benefits ; cardiovascular system



EH




HF

cell ; Anand
doxorubicin
blood transfusions
changes ; FM

devices ; heart failure
dXA
Liver disease

hz ; pna

Renal artery stenosis

surgery ; heart transplant recipients
hospital mortality
molecular mechanism
tertiary referral centre
EC
HF




breathing ; heart beat


heart failure ; Latin America


Heart

doctors
Nutrition ; heart failure
nordwest United States



heart failure


Heart failure

clin

trans

CHF
autonomic balance
competitive
intermediate frailty
HFpEF
ST2

dodson

LV fibrosis ;ANS mice

Jehovahs Witness ; anemia
inpatient medical conditions
hospital ; heart failure
cardiac transplantation
CO
frailty ;HF

Heart failure ; cognitive impairment
courant HF ; HF

Department of cardiology ; university hospital

Heart ; cardiac
Remote ischemic conditioning ; heart failure
air pollution ; heart failure

Sham-operated


policy


taxonomy
rates ; CHF
Heart failure ; uk

cardiovascular disease
hz ; MI

Heart failure


caspas ; heart failure
diuretic use ; heart failure
right heart failure ; pulmonary hypertension
Heart failure ; bisphosphonates

MR ; MS
hypertension
HF
Heart rate ; arterial pressure

Chronic HF
Cardiac amyloidosis
Robot-assisted training ; heart failure

Internal reliability ; cronbach
HFpEF
ejection fraction ; sex ; bNP
Pigs ; antiarrhythmic medication
beta blockade
CHF
surgical tactics ; circulatory arrest


systolic dysfunction


heart failure
implanted monitoring devices

patient safety ; conditions
hz ; afterload
strokes

RAS ; atherosclerosis
frailty ; heart failure
MicroRNAs ; heart failure ; disease management
cox regression
PSSS
heart failure ; ejection fraction
Cardiology ; Bromodomain inhibition ; heart failure

vasopressin ; congestive heart failure
Mitral stenosis ; heart failure
heart failure ; cardiovascular death
Trastuzumab-related cardiotoxicity ; breast cancer
Devices ; heart failure ;HF ; therapy
mortality ; sts HM
pde2 ; HF
Nights ; hospital
Heart failure ; public health
Postoperative normalization ; albumin
VET ; aortic pressure curve
physician continuity ; discharge
Medication ; sST2
réseau
Cardiac
spironolactone ; heart failure
eRK ; molecular scaffolds ; heart pathologie
Functional MS ; degenerative MR
chronic heart failure ; bisoprolol
Heart failure ;HF ; mortality
cox
physician ; hospital
Tolvaptan ; vasopressin
Arrhythmia-related costs
readmission metrics
readmission metric





ET ; CHF
HF


propensity
hgb ; baseline HRQoL
ejection fraction
biomarkers ; chronic heart failure
HF ; cardiovascular hospitalization
cardiac ; inflammatory biomarkers
mortality
heart failure
Pharmacological treatment ; acute heart failure
heart failure
off-pump ; sparing ; HeartMate II exchange
dialysis ; implantation
Coronary angiography
Hemodynamic ; Fontan
MS ; surgery ; echocardiography


heart failure ; cox
Nordic walking ; heart failure
Psychometric testing ; Self-Care of Heart Failure
multiorgan failure ; sepsis
acute kidney injury
VO2max
cox proportional hazards
Seattle Heart Failure Model
US healthcare
heart failure



abnormal cardiac


HR ;HF


biomarkers
mAIN oUTCOME ; temps ; tug
ESRD
Heart failure ; ventricular ejection fraction
mAIN
systolic HF

implantation
postsystolic
medication ; resting hemodynamics
pathophysiological origin
Mice ; aac ; cardiac hypertrophy
AHA ; ESC
Physician ; heart failure
skeletal muscle abnormalities ; circulation
Readmission ; hospital ; heart failure
progressive disease ; hypertension ; kidney failure
chronic kidney disease ;CKd
gross income ; expenditure ; health

abnormal HR ; cardiac death
circulation
toxicity ; systemic blood pressure



nord America
cPGs
MS

acute heart failure
patients ; heart failure
stand-alone diagnostic devices ;HF
heart failure
HF
endothelial ; flow-mediated dilatation
Race ; spironolactone ; heart failure
Patients ; heart failure ; cardiac rehabilitation
Rhythm- ; rate-control

avantages ; anemia ; heart disease
patients ; hf
Myocardial infarction ; Wistar rats
lVAD
new-onset ; AI
sinus rhythm ; AF
public reporting

care management ; telehealth ; medicare
filling pressures
ingenuity
hz ; chromatin hyperacetylation
nursing
acute heart failure

MS
grs ; CV ; AF



mortality

QRs ; benefit

CHF ; unilateral renal DNx ; cardiac autonomic balance
Mitral regurgitation ;HF
renin-angiotensin-aldosterone system ; heart failure
anaerobic threshold ; heart failure
MS
af ; echocardiographic examination

économique savings ; coût
PVf ; recovery ;PB

congenital heart lesions
MS ;HF ; ms
ICU
bioinformatic ; microarray ; heart failure
cardiovascular events
diuretic use ;HF
CAD ; systolic HF
resistin ; inflammation ; metabolism ; heart
st2 ; BB therapy
Heart block ; pulmonary artery snared ; BiVP

ct ; dialysis-dependent
beta-blockers
CHF
RM
hf
Cardiac ; pressure-volume conductance catheter system
idiopathic dilated cardiomyopathy
unfolded protein ; cardiac sodium current ; heart failure
hypoalbuminemia ; heart failure
hypertensive LV dysfunction ; MR ; MS
cd ; hf
angiotensin receptor ; neprilysin inhibitor ; heart failure
Western blot ; immunohistochemistry ; electron microscopy
diastolic dysfunction ; peripheral artery disease
ischemic cardiomyopathy
hff
heart transplant ; ECCT
proteome ; HDl particles ; shotgun ;LC-MS
HF
Southeastern Minnesota residents ; hf
branch ; electrical activation
hHF ; dPP-4 inhibitors ; drugs
proteins ;TAC
Cardiac cachexia ;cc
cardiac remodelling
dialysis

coronary disease ; heart failure
ff ; FM ; body weight ; CC
multihospital ; heart failure
Protective effects ; ed ; endothelial function
MS ; mva
social support ; exercise
heart rate
cRF
Mediterranean ; DASh
rehospitalization
nitroxyl ; hno ; heart failure
Cardiac-resynchronization therapy ; heart failure
odds ; hospital clustering
change ; lVET
Blacks ; VO2
physician continuity ; urgent readmission ; discharge ; heart failure
hf ; HFpEF
hospital-to-Home ; hospital readmission reduction ; congestive heart failure
hospitalization ; heart failure
diabetes ;EO-cFUs
patient safety
transplants


trastuzumab-related CHF
hospitals
Peak VO2
pharmaceutically
financiers
Coronary artery disease ;cad ; systolic heart failure ;HF
hypoalbuminemia ; lVAD
psoriasis ; atherosclerosis ; cardiovascular events ; Rotterdam
mortality ;HF hospital admissions ; transplant ; ventricular assist device
Heart failure ; rheumatoid arthritis ; tNF
holosystolic murmur ; heart
death ; non-fatal stroke ; heart failure
remodelling ; hf ; haemodynamic ; neuronal stressors
mortality
ventricular function ; body composition ; heart failure
Fat ; cachexia ; ventricle ; heart failure
atrial fibrillation ;AF ; heart failure
ECCT ; advanced heart failure therapy
heart transplantation ; left ventricular assist device
Exercise intolerance ; chronic heart failure
avd ; VVD ; co ; free wall
resistin ; heart failure
eCGs ; electrocardiographers
ventricular assist device ; right ventricular support
ESRD ; hf
Wilcoxon
subclinical atherosclerosis
Renal artery stenosis ;RAS ; peripheral arterial disease
ECCT ; cardiac transplant recipients
eplerenone

extubated ; blood loss ; transfusion
technique ; exchange malfunctioning HeartMate ; lVADs
Heart failure ;HF ; cardiovascular hospitalization
VEGF inhibition ; cardiac function ; remodeling
β-blocker ;BB ; sST2
miRNAs ; cardiac
cPET guiding exercise rehabilitation ; CHF
heart failure ; ejection fraction
Patients ; heart failure
Pediatric heart failure ;HF
regulatory subunit ;RI ; hf
discharge ; follow-up
bromodomain proteins

heart failure
bt ; DT ; implantation

hypotension
biomarkers ; HF
hf
ST2
économique
medications ; heart failure
mortality
coronary heart disease ; stroke ; heart failure
MLHF
septal defects
mortalité ; iCD-HF
unlateral renal denervation ; autonomic balance ; rabbits ; heart failure

trastuzumab
hCT germline DNA
Heart failure disease management
Renal DNx ; circulating plasma ; CHF-inv rabbits
hf
blood work ; medication
NP ; ED
Cardiac hypertrophy ; energy metabolism
lVAD implantation
HDL-bound malondialdehyde ; HDL-induced ; EC
renal dysfunction ; transplant morbidity
CAD ; CAD


hospital discharge
hospitals
avantages ; anemia ; heart disease
Right atrial myxoma ; pulmonary embolism ; right heart failure
Nfat ; mir-25 ; transcription factor ; Hand2 ; heart failure
resistin ; decline ; ejection fraction
Orthotopic heart transplantation ; oHT ; end-stage heart failure
Myxomas ; right atrium ; pulmonary arterial vasculature
readmissions ; follow-up visits ; heart failure ; readmission
lVAS ; bridge to transplantation
Cardiac ; Mammalian enabled ; mena ; heart failure
cPCs ; functional capacity ; VO2
dysfunction ; pump ; driveline injury ; pump replacement
canine ; chronic heart failure ; tachycardia
Nicorandil ; doxorubicin
EH ; hpEF
eAST ; rhythm control therapy ; cardiovascular complications ; AF
radiological signs ;HF
diuretics ; heart failure ;HF
fees
heart failure
Framingham Heart Study ; hf ; EF
hf
aCR ; CMS
caspase ; paced myocardium
heart failure ; aging ; body composition
hHF ; saxagliptin ; sitagliptin
Heart ; heart failure ; arrhythmias
ischemic ; inflammatory abdominal ; MT
ed ; intubations ; congestive heart failure
MedLine ;EMBAse ; cINAHL
aCP ; clinical practice
coronary artery disease ;CAD

clinical change
ed visits ; CHF
QRs ; ms
Medicare ; post-acute care transfer policy
vegetables ; nuts ; mortality

degs ; osprey ; réseaus

World Health Organization ; hf ; LA

implantation ; cRT
benefit
iron
hospital discharge ; patients ; heart failure
LV ; filling pressure ; hz
Soluble ST2 ; ambulatory patients ; heart failure
echocardiograms ; reverse remodeling
Titin hypophosphorylation ; myocardial DD
ventricular contractile reserve ; pulmonary hypertension
bottleneck stent ; chronic myocardial ischemia ; heart failure ; pigs
QT intervals ; SD ; QT intervals ;SDQT
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
benefit ;RAS ; β-blocker uptitration ; hpEF
injections
pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis
cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure
NOc ; admission to discharge
HRQoL ; hgb
inpatient records ; HF
skeletal muscle mass ; VO2
emergency cardiac catheterization
psychosocial factors ; exercise ; heart failure ;HF
heart failure ; Canadian Cardiovascular Society
active
aRIC HF
atrial fibrillation ; pacemaker
mortality ; iCD-HF
cardiovascular
AF-free ; catheter ablation ; sinus rhythm
body mass index ; cRF ; treadmill exercise
human myocardial tissue ; pKA
paediatric cardiac transplants
ventricular-arterial coupling ; SV
diastolic failure ; cardiomyopathic restriction
autonomic nervous system activity ; QTV
pneumonia ; conditions
mapping ; myocardial fibrosis


SD

ethics Rounds

biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
Heart Failure ; Pathophysiology ; Medical Treatment Guidelines
anemia ; heart disease ; American College of Physicians
heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
end-stage renal disease ; outpatients ; systolic heart failure
rvpo ; BiVP ; co ; RS synchrony ; CS
renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
resistin ; acute anthracycline-induced cardiotoxicity
acute autonomic nervous system modulation ; QTV ;HF
Heart ; aortic blood flow ; doxorubicin

Myocardial pde2 expression ; hf
BAT ; sympathetic outflow ; parasympathe
echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
cardiovascular death ; hf ; btes
heart failure ; high-density lipoprotein
Neurohormonal abnormalities ; congestive heart failure ; chf
parasympathetic neurotransmission ; acetylcholinesterase inhibition
LVEF ; long-term mortality
Mediterranean ; DASh ; mortality ; heart failure ; Womens Health Initiative
Jehovahs Witness ; sickle cell disease ; anemia
miRNAs ; heart failure
dobutamine ; furosemide ; oxygen flow
Health Buddy Program ; ED
ca2 ; currents ; rad ; congestive heart failure
cPCs ; diabetes
resistin ; anthracycline-treated breast cancer ; cardiotoxicity
pulmonary artery ; right pulmonary artery
mRI scanner ; heart failure

congestive heart failure ; chf
muscle-wasting syndrome ; acquired heart failure
Frailty ; elderly ; health
ed ; CHF ; intubation
bisoprolol ; mortality
Health Buddy Program ; content-driven telehealth system ; care management
Medicare fee-for-service
physician continuity ; conditions ; hospital discharge
heart failure
PSSS ; social support ; btes
cardiac stress ; β-AR drive
chromatin subproteome ; mouse heart
co correlated ; septal wall ; avd ; free wall ; CS ; VVD
LV ; echocardiography
transplantation ; circulatory assist device
biventricular pacing ; left heart twist ; strain ; porcine ; right heart failure
etiologic ; RV failure ; left ventricular dysfunction
cPCs ; functional capacity ; heart failure ;HF
inhibition ; protein kinase ; guanylate cyclase
circulating progenitor cells ; heart failure
Stress ; doppler echocardiography ; pulmonary hypertension
systolic ; diastolic mitral leaflet
morbidity ; mortality ; hf
ctnt ; NT-probNP ; HF
confidence intervals ; CIs
radiological signs ; HF
inhospital mortality ; bNP
Mortality ; aCS consultation
ventricle ;RV ; cardiac function
coût ; patients ; heart failure ;HF
RV dysfunction ; weight loss ; fat
HR reduction ; beta blockers ; hFrEF
cardiopulmonary exercise ; heart failure

i-MIg ; myocardial
myocardial diastolic dysfunction ;DD
heart failure
ST2
black race ; mortality
Nursing-sensitive outcome change ; hospitalized older adults ; heart failure
therapeutic ; fluid
resistin ; chemotherapy-induced heart failure ; mice ; breast cancer
social support
pressure ulcers ; surgical
HF ; valve plasty ; MS ; mva
p ; refractory ; end-stage congestive heart failure ; chf
insurance status ; comorbidities
beta blockers ; mortality ; heart failure
transcatheter
futility ; data ; safety monitoring board
complication
chelation ; heart iron
MT ; consultation ; abdominal
Timed up ; Go ; chronic organ failure
NYha

mortality
ventricular ejection ; acute heart failure ; precapillary pulmonary hypertension
surgical correction ; aortic valve insufficiency ; left ventricular ; implantation
ejection fraction ; cardiac resynchronization therapy ; heart failure
functional capacity ; mwt
hff ; dietary sodium restriction ; ventricular
magnetically Levitéd left ventricular Assist System ; HF
CHF atrial explants ; sham explants
chronic heart failure ; chf ; sympathetic tone ; autonomic imbalance
Heart failure ; mortality ; cardiovascular diseases
extracorporeal membrane oxygenation ; bridge to recovery ; infarction-related refractory right heart failure
echocardiographic ; invasive hemodynamic
INVESTIGAtions ; cardiac catheterization ; thrombotic obstruction ; right coronary artery
California office of Statewide Health Planning and Development ; Patient Discharge
Fontan failure ; ventricular function ; liver disease
nursing ; hospitalized ;HF
pacing-induced dilated cardiomyopathy
electromechanical delay ; dyssynchronous heart failure
trastuzumab ; cardiac

économique ; af ; heart failure ; Québec
cardiac Mena deletion ; cardiac dysfunction ; hypertrophy
bundle-branch block ;LBBB ;LBBB ;LBBB
protein ; Western blot ; DNA fragmentation ; tunel ; autopsy
Chinese herbal medicine ; adjunctive treatment ; dilated cardiomyopathy ; heart failure
implantable cardioverter-defibrillator deactivation
EH ; CH ; cardiac filling pressures
right atrium mass ; prolapse ; tricuspid valve ; stenotic physiology
NT-probNP
heart failure ; altered protein kinase
HF
temps-varying Seattle Heart Failure
dopamine ; nesiritide
chemical instability ; cogeneration ; nitrite
neurological ; cardiovascular
cox regression ; cardiovascular events ; psoriasis
class i cPG ; hf
HDl-induced ; flow-mediated dilatation ; ET
aHF

BETs ; mouse TAC ; hf
coût-effective
cardiac nurses
consultations
transfusion ; mortality
Czech Republic
MADit-cRT
closure
UM/va ;va-RT
heart failure
Western blots ; monoclonal antibodies ; Ser83 phosphorylation ;HF
preoperative serum albumin ; ventricular assist device implantation
New York Heart association
MS ; ring annuloplasty ; ischemic MR ; LV
Paco2 ; cerebral blood flow ; carotid bodies
vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure
pathophysiology ; hf
ed physicians ; suburban hospitals ; New Jersey ; New York
psoriasis ; smoked ; diastolic blood pressure ; body mass
Exercise intolerance ; heart failure
echocardiography ; implantation
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; pediatric heart failure
cox models ; ST2 ; functional capacity
TM interventions ; sts
HRQoL
NT-probNP ; circulation ; HF
changes ; energy metabolism ; heart failure ; hypertrophied heart
MS ; LV ; functional MS
PAD ; ankle-brachial index
HR ; ivabradine ;TAC
mechanical cardiac support ; renal
ECmo ; VAD ; ECmo+VAD
mortalité ; morbidité ; cancers ; budget
anticoagulation ; therapy ; heart disease
inotropic effect ; beta blockers ; heart failure
interleukin receptor ; ST2 ; beta-blocker therapy ; chronic heart failure
heart failure ; systolic heart failure
rhythm-control ; rate-control
hemoglobin
Functional MS ; medical treatment ; surgical
HF ; health service provision ; HF ; la
Heart failure ;HF
heart failure ;HF
CF lVAD ; AI ; heart failure
anemia ; heart disease
ventricular dilatation
ventricular assist devices ; device therapies
implanted
renal dysfunction ; mechanical cardiac support
HF
readmissions ; hospital rankings ; pay-for-performance
cfa
PB ; hf ; pattern generator
Reasons
coagulability
iCD

bNP ; NT-probNP ; biomarkers ; heart failure
Cardiorespiratory fitness ; body mass index ; heart failure mortality ; Cooper Center longitudinal Study
pro-adrenomedullin ;MR-proadm ; fm

Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
implantable cardiac defibrillator
ATP demand ;XO-mediated ROS ; mitochondrial respiration ; contractile
cardiovascular ; diabetes mellitus ; hypertension ; hyperlipidaemia
systolic HF ; unclear etiology ; coronary angiography
atrial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
ejection fraction ;EF ; infarct ; collateral growth ; myocardial perfusion
Circulating ; n-terminal ; natriuretic peptides ; heart failure
heart failure ;HF ; ventricular ejection fraction ; hpEF
end-stage heart failure ; implantation ; long-term ventricular assist device
HF ; cardiac murmurs ; blood pressure
adenylyl cyclase ; g-protein coupling
HF ;VT ; beat-to-beat ; QT
biventricular dysfunction ; HeartMate
TUg ; COPd ; CHF ; cRF
tension-overload-induced heart failure
Nursing ; social mandate ; nursing
hemodynamically unstable ; cPR
isoproterenol ; cXL-1020 ; myocytes ; hearts
cardiac angiogenesis ; coronary perfusion ; cardiac fibrosis
instability ; heart failure ; ventricular tachycardia
Pyridostigmine ; myocyte diameter ; collagen density ; ventricle
Exercise intolerance ; hfEF ;qol
energy substrate metabolism ; working hearts ; aac
SCHFI
CAD ; CAD
diabetes mellitus ; cardiovascular disease
CVd ; psoriasis
haemodynamic ; pulmonary
prediction rule
Rotterdam ; psoriasis ; cardiovascular outcomes
HR ; tNF ; nbDMARD
aCS ; MT ; VAD
hospital ; cardiac specialty hospital ; rural South Dakota
medical records
ECmo ; egFR ; egFR
administration ; trastuzumab-related CHF
acute HF
biomarker-guided
hospitals

sudden cardiac death
HF-related cachexia ; RV ; body composition
hospital mortality
rehospitalization
cognitive impairment ; mortality
sonographic ; histological ; functional abnormalities
natriuretic peptide
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
Spironolactone ; hyperkalemia ; acute kidney injury
bNP ;PAD ; bNP ; hf
sympathetic ; parasympathetic activity ; hf
EH ; systolic blood pressure ; renal impairment ; hypertension
ambulatory HF
mouse ; HF ; transition ; LV hypertrophy ; HF ; hd
ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
heart transplantations ;LV ; implantations ; heart failure
chronic myocardial ischemia ; heart failure
HFpEF
mechanical cardiac support ; renal function ; end-stage heart failure
surgical revascularization
hgb ; kccq
Morpholino-based knockdown ; nucleolin ; protein expression
clinical prediction rule ; CAD ; cause ; systolic HF
pump-exchange technique ; redo sternotomy ; cardiopulmonary bypass
MS ; medical treatment ; hf ; functional MS
parasympathetic function ; HF
aggressive medical treatment ;HF ; HF ; ms ; mva
jugular venous pressure ; peripheral oedema
Heart failure ;HF
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
Fontan circulation ; sVR ; cardiac index
lVAD ; biventricular
mineralocorticoid receptor antagonists
abnormalités ; heart ; nontraumatic death
Fontan circulation ; skeletal muscle mass ; metabolic abnormalities
HeartMate II lVAD

health insurance ; health system data ; ue ; Food and Drug Administration
NT-probNP ; ED ; acute heart failure
blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic status
albumin ; lVAD
réseau ; Cytoscape ; DAVID
cardiovascular conditions ;HF
patient safety
HF-induced remodeling ; EMd
right heart circulation ; right heart failure
Raf-MEK1/2-ERk ; remodelling
MI ; late-onset ; MI ; hf
Bisphosphonate ; heart failure
coût
sustainability ; commissioning
maladaptive molecular
Xanthine oxidase inhibition ; ventricular systolic ; diastolic ; cardiac
heart failure ; preserved ejection fraction ; doppler echocardiography
heart failure ;HF ; Heart Failure Adherence ; retention Trial ;HARt
HF ; preserved ejection fraction ; hpEF ; hypertension
NYha functional class ; quality-of-life score
Myocardial infarction ; left anterior descending coronary artery occlusion
hpEF ; breathlessness ; fatigue ; fluid retention
immunodetection ; NT-probNP ; antibodies
Nordic walking ; cardiac rehabilitation ; heart failure
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
β-Blockade ; cardiac angiogenesis ; heart failure ; VEGF
myocardial ischemic events ; cardiac resynchronization therapy
aortic valve surgery ; new-onset ; lVAD
unloading ; heart ; HR reduction ; systolic heart failure
spironolactone ; systolic heart failure
Heart failure ; medicine ; atheromatous coronary disease
Heart failure ;HF ; Latin America ; la ; health service planning ; HF
rehospitalization ; medicare fee-for-service beneficiaries ; skilled nursing facilities
hz ; ct
palliative
HFpEF
oxidative stress ; GTPase Rac1 activity ; hearts ;ANS mice
circulating mediator of insulin resistance ; monocytes ; inflammatory stimuli
cardiovascular death ; urgent cardiac transplant
medications ; heart failure ; NCDR PINnaCLE
nonselective ; beta-blockers ; cardiac sympathetic activity ; heart failure

transformed
Intravenous iron ; heart failure ; iron deficiency
heart failure ; Emergency Department ; ed ; ed
stress conditions ; remodelling ; heart failure
degs ; non-ischemic ; ischemic heart failure
psoriasis ;UV
RV dysfunction ; weight loss ; abnormal body composition ; hf


diastolic dysfunction ; hfEF
adrenergic receptor blockade ; heart failure ;HF
ventricle overload ; stroke ; ventricular ejection time ; lVET
NT-probNP ;HF ; immunoprecipitation
Chromatin-associated proteins ; chromatin structure ; DNA
p ; complications ; therapy ; hf
pulmonary hypertension ;PH ; heart failure
robot-assisted gait therapy ; Lokomat® system ; heart failure
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
ET ; HDL function ; ET ; CHF-NYha-IIIb ; HDL
Cardiac failure ; diabetes ; diabetes ; heart failure

lVET ; death ; ICU
congestive heart failure
aim ; implantable cardioverter-defibrillator deactivation
mitochondrial structure ; sarcomeric
heart failure ; ejection fraction
gut ; inflammation ; heart failure ; heart failure
pPR ; aCR ; CMS
mortality ;LCx ; LAD ; two-vessel disease
CHF ; emergency department ; ed ; intubated
CHF ; therapeutic interruption ; neurohormonal systems
zSF1 rats ; heart failure ; ejection fraction
physician follow-up after discharge ; death ; readmission ; heart failure
heart magnetic resonance imaging ; chelation choices ; heart disease ; thalassaemia
arterial tonometry ; lVET ; precapillary PH ; heart failure
Cross-talk ; heart ; adipose tissue ; cachectic heart failure ; body composition
mutant mice ; Hand2 ; heart muscle cells
transoesophageal echocardiography ; shunts ; patent ; thrombosis
implantration ; heart rate ; renal function ; spironolactone
dialysis ; echocardiographic
microRNAs ;miRNAs ; heart failure
PARADIGm-HF ; chronic heart failure ; Chronic heart failure ; cardiology
ambulatory HF ; left ventricular ejection fraction
New Zealand White rabbits ; renal DNx ; pacing-induced CHF
QT variability ; qTV ; repolarization lability ; QTV ; cardiac death
Beta-blocker
mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
cardiovascular disease
processes of care delivery ; poc technologie
psoriasis ; cardiovascular disease ;CVd
AMI mortality
readmissions

Rhythm control therapy
septal

cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
LV diastolic dysfunction ; filling pressures ; doppler echocardiography
Cardiac magnetic resonance ; heart failure ; ejection fraction
Myocardial collagen ; collagen cross-linking
RAS-blocker uptitration ; hFrEF ; HFpEF
Hemoglobin ; heart failure ; HF-ACtion
Systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
Plasma ; hf
pde2-overexpressing cardiomyocytes ; norepinephrine-induced hypertrophic
heart failure ; CLCNKA sNP
GDMT ; GDMT ; GDMT ; BAT
hz
transduction ; signalling proteins
alendronate ; alendronate ; heart
cardiovascular disease ; dRS
index admission

beta-blocker therapy
heart failure ; bisphosphonates
frailty ; heart failure ;HF
miRNAs ; cardiac remodeling ; heart failure
hf
clinical diastolic dysfunction
AlphaLISa ; immunoassays ; NT-probNP
Fontan ;SAF
death ; c-statistics
sinus rhythm ; antiplatelet agents ; anticoagulants
implantable cardioverter-defibrillator deactivation
heart failure ; left ventricular ;LV ; ejection fraction
cardiotoxicity ; doxorubicin ; anti-neoplastic agent ; cancers
aCS ; oHT ; transplant ; MT ; VAD
natriuretic peptides
RAS- ; β-blocker
β-Blocker-induced enhancement ; cardiac angiogenesis ; therapy ; cardiac function
hf ; rheumatoid arthritis ;RA
expression ; Bax ; bcl-2 proteins ; dogs
PRInciPAL FINDINGs ; hospital rates ; hf ; CMS ; conditions
regulation of feeding ; anti-inflammatory effects ; CHF
lifesaving drugs ;HF ; ejection fraction ; hrEF
hyperkalemia ; acute kidney injury ; spironolactone
Renal denervation ; dx ; CHF
MT ; VAD ; aCS consultations
refractory congestive heart failure ; peritoneal dialysis
Mammalian enabled ; mena ; cytoskeletal actin dynamics ; heart failure ;HF
heart failure ; left atrial pressure
Heart failure ; preserved ejection fraction ; hff ; cardiovascular reserve
LV ; diastolic dysfunction ; hfEF
physician follow-up after discharge ; physician continuity ; heart failure
ambulatory iCD ; mortality
ARNI ;angiotensin-receptor neprilysin
Gastrointestinal bleeding ; ventricular assist devices
nicorandil ; cytotoxic effect ; doxorubicin ; Ehrlich carcinoma
Myxomas ; cardiac benign tumors ; left atrium
fees ; preserved ejection fraction ; hpEF
bNP ; NT-probNP ; coronary artery disease ;CAD

NT-probNP
ECCT
aerobic capacity ; left-hand grip ; body weight ; waist circumference ; anxiety
Process redesign
Myocardial loss ; iRS1 ; iRS2 ; heart failure ; maPK ; insulin resistance
heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy
Functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation ;MR
ICU admission ; precapillary PH ; heart failure
heart failure-related hospitalization ; ventricular ejection fraction
Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbidity
doppler imaging ; left ventricular filling pressure ; systolic heart failure
lean ZSF1 ; obese ; zSF1
heart failure ; preserved ejection fraction ; hfEF
Kansas City Cardiomyopathy ; heart failure ; ejection fraction
myocardial pde2 ; intracellular antiadrenergic therapeutic stratégie ; hz
benefits ; spironolactone
HF
IE ; heart failure ;HF ; cRT-d
pharmacologic treatment ; pharmacologic
Mechanical dyssynchrony ; QRs complex ; cRT
coronary occlusion ; collateral growth ; stent occlusion
carotid intima-media ; psoriasis
transfusions ; heart disease
VO2 ; joint effect
PVf ; PB ; BP
chronic heart failure ; Hungary
RV dysfunction ; cardiac cachexia
Remote monitoring ;RM ; heart failure
eCG ; ct
sST2 ; b ; cardiovascular
breast cancer ; trastuzumb-related CHF
HF remodeling ; EMd ; dyssynchronous failing heart
acute heart failure ; aHF ; heart failure ;HF
angiogenesis ; post-myocardial infarction ; heart ; heart failure
aldosterone antagonist ; heart failure
surgery ; hf ; hypertension ; vasodilators ; diuretics
Genetic susceptibility ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
HR ; beta-blocker therapy
pde2 ; failing hearts ; acute β-AR
psoriasis ; atherosclerosis ; cardiovascular
anemic ; iron-deficient ; heart disease
heart failure
egFR ; diuretics ; hypertension ; ESRD
trastuzumab ; CHF ; nontrastuzumab
e-cFUs ; mortality
point-of-care systems ;NP ; ed ; outpatient settings ; acute heart failure
heart failure ; ejection fraction ; myocardial infarction
lVAS
black race ; hh ; cardiovascular mortality
cardiac disease ; heart failure
hff
physician adherence ; HF cPGs
HF ; HF ; HF mortality
HDl ; CHF ; ET ; HDl-mediated vascular effects
coronary artery disease ; systolic heart failure
Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic guidance
arterial compliance ;TAC ; end-systolic elastance ; ees
biventricular support ; HeartMate ; lVAD ; CentriMag RVAD
Renal dysfunction ; long-term mortality ; myocardial infarction ; coronary artery bypass grafting ; caBG
cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; hpEF
isoprenaline infusion ; SDQT ; hNorm ; HF
Renal dysfunction ; cardiovascular events ; caBG
Pyridostigmine ; vascular endothelial growth factor ; ventricle ; myocardial angiogenesis
egFR ; VAD ; ECmo ;VAD ; ECmo
CHF ; international Classification of Diseases
RV dysfunction ; body mass index ; fat mass index ; cachexia
cRF ; HF mortality ; HF
Robot-assisted gait therapy ; Lokomat® System ; heart failure
cardiac growth ; plasticity ; disease ; chromatin remodeling
idiopathic dilated cardiomyopathy
dopamine ; nesiritide
MEDline ; eEMBAse ; cochrane databases ; clinical trial registries

HF ;HF
Ea ; TAC ; HR ; ees ; ivabradine
Care management ; content-driven telehealth technologie ; health outcomes ; high-cost Medicare
ERC ; epicatechin
biomedical reasons
myocardium ; pKA
atrial fibrillation ; carvedilol ; metoprolol
heart failure ; implantable cardioverter-defibrillator
functional MS ; valve plasty ; degenerative MR ; LV
HeartMate II insertion ; implantation
end stage heart failure ; heart failure ; public health ; europe ; nord America
st-segment-elevation MIs ; Killip class ; conditions
heart failure ; mechanical support devices ; Cardiology-cardiovascular surgery ; Heart failure
elastic N2Bus segment ; PEvK
Self-Care of Heart Failure index ;SCHFI
proteomics
HeartMate ; left ventricular assist system ; lVAS ; heart failure
Nicorandil ; mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats ; cardioprotection
pharmacologic management ; acute HF ; chronic HF
arterial elastance ; pulsatile afterload ; heart ; pressure
cXL-1020 converts ; hno ; inactive ; cXL-1051
tNF antagonists ; HF ; hospital admissions ; nbDMARDs ; RA
ejection fraction
grs ; CV

mortality
nurses ; benefits
physician adherence
hf ; PAf biosynthetic enzymes ; lyso-paf-AT
myocardial infarction ;MI ; heart failure ;HF
cardiac magnetic resonance imaging ; mapping ; invasive hemodynamic assessments
Heart rate reduction ; heart failure ; ejection fraction ; beta-blocker hypo-response
RAS ; hypertension ; nephropathy ; congestive heart failure
brain natriuretic peptide ; bNP ; creatinine
mADIt-cRT ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
NT-probNP ; MR-proanp ; MR-proadm
Isoelectric focusing ; RIα ; ser77 ; ser83 ; phosphorylation
SDQT ; SD ; RR ;SDRR ; QTV ; heart
aUCs ;septal ; QRs
Logistic regression models
IVc occlusion ; co correlated ; twist ; apical rotation ; RS ; RS synchrony ; CS
hospital stay ; congestive heart failure
diuretics ; modulate HF
hospital ; readmission ; patients ; heart failure
gastrointestinal bleeding
ms ; cardiac events
egFR ; VAD ; edmo+VAD ; renal
sST2/low-dose BB ; sST2/high-dose BB
CHF ; ED ; CHF ; intubated
Physician volume ; mortality ;HF ; noncardiologist physicians
zebrafish ; nucleolin ; genomic reprogramming
LV ; ejection fraction ; PCWP
hf ; complicating AMI ; mortality
emergency department ; acute heart failure
cardiopulmonary exercise ; muscular strength ; quadriceps force
public health ; air pollution ; cardiovascular health
eCG ; ion channelopathies ; cardiomyopathy
idiopathic dilated cardiomyopathy ; tuscany
hz ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
Morbidité ; mortality ;HFpEF ;HF ; EF
HF ;heart failure ; t2d ;Type 2 diabetes ; Skm ; skeletal muscle
heart failure ;HF ; inpatient ; outpatient
molecular biomarkers ; pathophysiology ; chronic HF
carvedilol ; metoprolol ; heart failure
Erythropoiesis-stimulating agents ; anemia ; heart disease
intravenous iron ; heart failure
mitral valve plasty ; degenerative mitral regurgitation
in-trial resource utilization ; coût ; Québec Health Insurance Board ; costs ; Ontario Case Costing Initiative
knockdown ;BET bromodomain-containing protein ;BRd4 ; cardiac tissues
RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction
readmission
end-stage heart failure ; pediatric mechanical cardiac support
économique models ; lVAD
multiparametric echocardiographic score ; ct
ejection fraction
af ablation
If-channel inhibition ; hemodynamic status ; heart failure ; ejection fraction
tidal respiration ; gadolinium-chelate contrast agent
Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
Medicare inpatient ; hf admissions ; acute care hospitals ; United States
catheter ablation ; atrial fibrillation ; heart failure ; ejection fraction
dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; ROse acute heart failure
DAPc ;dystrophin-associated protein complex ; sarcomeric
mouse ; hh ; hh ; salt loading ; uninephrectomy ; ANG
Benefits ; HF ; ejection fraction ; pEF
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat
echocardiographic ; response ; cardiac resynchronization therapy ; ct
baseline serum creatinine ; potassium
chromatin subproteomes ; heart failure ; proteins
Hum-retn mice ; cardiac mRNA ; inflammatory ; cell adhesion ; Retn
anemia ; chronic heart failure ;HF
University of Connecticut Heart Failure Center ; cardiologist ; heart failure
NT-probNP ; antibodies ; nonglycosylated
RV failure ; intrinsic left ventricular dysfunction
PD ; weight loss ; diuretic response ; edema
Chronic heart failure ; transforming growth factor beta-dependent yield ; functional decline ; atrial explant-derived
HFpEF ; kccq
HeartMate II lVAD ; CentriMag RVAD
patients ; heart failure
HF ; MI ; ejection fraction ;EF
Mortality ; inpatient admissions ; emergency department ; ed
nbDMARD ; tNF antagonist
trastuzumab ; cardiotoxicity ; congestive heart failure ; chf
pyridostigmine ; methylatropine ; propranolol ; cardiac sympathovagal balance
uPR ; protein kinase ; ER kinase ; perk ; calreticulin ; CHOp ; HF
myosin binding protein-C phosphorylation ; ser23/24 troponin ; phosphorylation ;HF
ecardiographic ; n-terminal pro-brain natriuretic peptide
Phosphodiesterase-2 ; failing hearts ; beta-adrenergic responses ; cardiomyocytes
carvedilol ; thromboembolic events ; heart failure ; β2-receptor haplotype
hFrEF ; exercise ; resting HR ; beta-blocker therapy
PAf ; metabolic enzymes ; heart failure
XO inhibition ; cardiomyocyte bioenergetics ; LV ; aCF
trials ;rcts
cox hazard models ; temps ; ESRD ; death ; ESRD ; death ; ESRD
preoperative renal dysfunction ; stroke ; myocardial infarction ; heart failure ; caBG
heart failure ;HF ; cardiopulmonary exercise ; anaerobic threshold
Patients ; heart failure ; heart failure ; nurses ; cardiology services
HF ; pyridostigmine ; stroke ; ejection fraction ; cardiac output ; contractility ; left ventricle
cardiac deaths ; atherosclerotic CAD
ms ; mva
Womens Health Initiative ; hf
CHF ; infarcted animals ; left ventricle ; end-diastolic pressure ; hg
RV ; pathophysiologic mechanisms ; RV dysfunction
dialysis-dependent patients ;HF ; cRT implantation
Peak oxygen ; oxygen pulse
économique climate ; NHs ; behavioural-change ; chronic disease
hCT CHF ; hCT ; City of Hope

pigs ; inferior vena cava ;IVc ; snared ; CO
doxorubicin ; ip ; serum resistin ; Hum-retn mice
costs ; high-volume physicians ; hospital
nutritional abnormalities ; CHF ; fat
deactivation
aldosterone receptor antagonists ; morbidité ; mortality ; systolic heart failure
sCN5a ; uPR ; downregulation ; cardiac genes ; HF
eas ; rhythm control therapy ; af ; cardiovascular complications ; AF
albumin ; inflammation ; hepatic function ; implantation
Right ventricular ;RV ; insertion ; left ventricular assist device ; lVAD
tAPse ; PASp ; passage ; nonsurvivors ; PASp ; tAPse
cox ; hazards
lipolysis ; energy expenditure ; natriuretic peptides ;NPs ; CC
CV ; non-fatal stroke ; heart failure
hearts ; Mena ; cardiac injury ; Mena ; HF pathophysiology
biomarkers ; molecular dysfunction ; chronic HF
ST2 ; c statistic ; discrimination
mAIN oUTCOME ; grs ; index beat ; CV ; cox
non-ischemic ; ischemic heart failure ; biomarkers ; heart failure
VAD ; ECmo+VAD ; ECmo
air pollution ; cardiovascular health ; acute myocardial infarction
kccq ; Kaplan-Meier curves
RAS ; doppler ultrasonography ; tomographic angiography ; magnetic resonance angiography
Testosterone therapy ; exercise rehabilitation ; chronic heart failure ; testosterone
pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone
AMI ; heart failure ; kidney infection ; UTI
proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural
IC ; multicenter Automatic Defibrillator implantation ; Trial-Cardiac resynchronization Therapy
Olmsted County ; Minnesota ; MI ; HF
Health Buddy Program ; chronic obstructive pulmonary disease ; congestive heart failure
hf
fréquence ; death ; hf ;AMI
neurohumoral blockers ;HF ; co-morbidity burden
age-dependent ; left ventricular ejection fraction ; long-term mortality ; heart failure ; Heart Failure Survey ; ISrael
vascular endothelial growth factor ;VEGF ; transition ; compensatory hypertrophy ; cardiac failure
CAD
hypoalbuminemia ; ventricular assist device ; lVAD ; implantation
apoptosis ; heart failure

diuretic efficacy ; neurohormonal activation ; fluid
uPR ; channel mRNA splice ; cardiac ; hz
LVEF ; LVEF
lVAD ; transplantation eligibility status
BETs ; transcriptional pause release ; transcription ; pathological stress
eCG ; atherosclerotic CAD ; sudden cardiac death
hf ; index AMI ; mortality
ct-d ; IE ; defibrillator-only therapy
HR dynamics ; temps-domain ; HR variability ; risk
Cardiopulmonary exercise ; echocardiographic ; myocardial function ; ventricular filling
echocardiography ; ste ; BiVP ; ventricular pressure overload ;RVPO
atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
coronary revascularization ; hemodynamically stable
Obesity ; diabetes mellitus ; metabolic risk factors ; heart failure ; ejection fraction
sex ; EF ; bNP ; hf ; bNP ; sex ; EF
perk inhibition ; sCN5a ; kv4.3 mRNA ; mRNA ; mRNA splice
LVEF ; long-term mortality ; acute decompensated HF
expression ; hf ; Mena ; cardiac pathophysiology
salt loading ; uninephrectomy ; ANG II infusion ; cardiac function ; hz
echocardiographic score ; LV ; reverse remodeling
atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
HR reduction
bottleneck stent ; myocardial infarction ; antiplatelet medication
ANS mice ; LV ; fractional shortening ; lung weight
Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
Trastuzumab ; CHF ; nontrastuzumab
systolic heart failure ; spironolactone
dysfunction ; rad variant ; q66p ; congestive heart failure
functional enrichment ; programmed cell death ; degs
atrial fibrillation ; atrial fibrillation ; Stroke prevention Trial

RECENT FINDINGs ; intestinal morphologie ; permeability ; absorption ; CHF
anaerobic metabolism ; respiratory
ARNI ; cardiovascular mortality ; hospitalization ; heart failure
myocardial DD ; muscle strip stiffness ; titin hypophosphorylation
figures force
cardiac hypertrophy ; nucléaire
idiopathic dilated cardiomyopathy
high-volume physicians ; readmission
NP ; poc ; NPs
benefits
Kansas City Cardiomyopathy Questionnaire ; kccq ; HF ; EF ; hpEF
annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; ventricular contractile
biventricular support ; HeartMate ; lVAD ; CentriMag ; ventricular assist device ; VAD
Blood pressure ; arm cuff ; stroke volume ;SV ; ejection fraction ; end-diastolic volume ; echocardiography
fibrosis ; heart failure ; ventricular tissue ; trichrome blue histologic
sNP ; Ka renal chloride channel gene ; cCNka
HF
contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
NT-probNP ; dyspnea ; left ventricular dysfunction ; ed
pathological remodelling ; heart ; cardiac hypertrophy ; hf ; fibrosis ; inflammation
HF-ACtion ; hgb ; baseline HRQoL ; kccq
Circulating progenitor cells ; cPCs ; endothelial repair ; cardiovascular
right ventricular ;RV ; heart failure ;HF
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; emo ; renal
American College of Cardiology ;American Heart association ; RAS
functional MS ; valve plasty ; degenerative MR ; LV
EO-cFUs ; CD34 ;vegFR2 ; mortality
implantable cardioverter-defibrillator deactivation ; heart failure
functional MS ; valve plasty ; annular size reduction ; degenerative MR ; LV
fréquence ; heart failure ;HF ; biological
LV remodeling ; diastolic properties ; XO inhibition ; heart failure
SDQT ; HFVT ; HFVT ; hNorm ; fixed-rate atrial pacing

t1-mapping technique ; diffuse myocardial changes ; heart failure ; contrast agent
bNP ; inhospital mortality
is ; cRT-d ; heart failure
expenditure ; health ; gross national income ; hf ; LA
bt ; DT ; coût-effectiveness ; bt
af ; pharmaceuticals ; hff
blood pressure control ; lipid-lowering therapy ; smoking cessation ;RAS
coût-effectiveness
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
implantable cardioverter-defibrillateurs ;ICds ; cardiac resynchronization therapy ; cRT
Vascular endothelial growth factor ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
DASh ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
HFpEF ; echo-Doppler cardiography ; invasive haemodynamic assessment
RAS ; β-blocker uptitrations ; hFrEF ; HFpEF
exercise-induced PASp ; hg ; PASp
skeletal muscle sarcomere ; heart failure ; diabetes ; epicatechin-rich cocoa
Physician ; medically managed diseases ; hf
centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow ; artificial pulse
eplerenone ;HF-ref ; hyperkalemia ; wRF
mitochondrial complex ; activity ; aac ; phosphocreatine ; ATP
sST2/low-dose ; sST ; cardiovascular events
frail
QRs morphology ; cardiac resynchronization therapy ; cRT
hff ; longitudinal outcome-monitoring ; cardiac
RM ; discharged ; heart failure
acute heart failure ; aHF
embryonic gene programs ; pathological heart disease ; transcription factors
mdc
LBBB ; implantable cardioverter defibrillator-cRT
heart rate ;HR ; ivabradine ; systolic heart failure
cardiovascular death ; stroke ; heart failure ; myocardial infarction
heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; heart failure
Cardiac-resynchronization therapy ; ct ; chronic systolic heart failure ; QRs
PERK activation ; sCN5a ; kv4.3 ; mRNAs ; transient receptor potential cation ; m7 ; tm7 ; mRNA
implantable cardioverter-defibrillator ; Heart Function Clinic ; University Health Network ;Toronto
Exercise-induced PASp ; pulmonary hypertension ; ventricular contractile reserve
MI ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
biomedical treatment ; chm ; biomedical treatment ; dCM ; heart failure
ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ;HF
Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ;coRAL ; stenting ; RAS
mortality ; heart failure ;HF ; implantable cardioverter defibrillateurs ;ICds
therapeutic left-to-right interatrial shunting ; heart failure ; ejection fraction
Mediterranean ; Dietary Approaches to Stop Hypertension ;DASh ; mortality ; postmenopausal women ;HF
multiparametric echocardiographic score ; reverse remodeling ; cRT
Yorkshire swine ; implanted ; pacemakers ; ventricularly paced ; heart failure
renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
HF ; HF ; hf ; SH ; cd ; rheumatic fever
mortality ; readmissions ; costs
caloric restriction ;diet ; aerobic exercise training ; exercise capacity ; QOL ; hfEF
heart failure ;HF ; hemodynamic disorder ; dysfunction ; interconnected molecular pathways
medications ; heart failure ; ejection fraction
HFpEF ; diastolic filling time ; heart rate
mice ; cardiac myocyte-specific Mena overexpression ; tgtetMena ; cardiac pathologie
antiplatelet agents ; anticoagulants ; vascular
international Right Heart Foundation ; right heart failure
POc ; NP
LBBB ; QRs ; implantable cardioverter defibrillator-cRT
echocardiography ; cardiac diameters ; cardiac function
MEDline ; eEMBAse ; PsycINFO
life ; functional capacity

systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke
af ; heart failure ; financier burden
body weight ; FM ;fm ;cc

ventricular ejection fraction ; ventricular diastolic end diameter
eccentric ; ventricular hypertrophy ; heart failure ; ejection fraction
ventricular ejection fraction ; heart failure ; preserved ejection fraction ; hpEF
β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; failing heart
Mice ; cardiac hypertrophy secondary to pressure-overload ; abdominal aortic constriction ; aac
hgb ; kccq ; hgb ; HRQoL
patients ; heart failure ; hospital discharge ; readmissions
Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; cardiac index
changes ; myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous HF
ankle-brachial index ; pulse-wave velocity ; coronary artery calcium
truncated na+ channels ; unfolded protein response ; uPR ; electric remodeling ; hz
intermacs ; interagency Registry for Mechanically Assisted Circulatory Support
allopurinol ; LV contractile function ; XO-mediated ROS ; myofilament
techniques ; HFpEF ; long axis function ; exercise
physicians ; patients ; advanced heart failure
fréquence ; mortality ; hazard ratio ; mortalité
af ; hyperkalemia ; hypokalemia ; spironolactone
g-protein-coupled receptor kinase-2
NT-probNP
sCN5a ; angII ; hypoxia ; uPR
isolated heart transplant
bNP ; diastolic dysfunction

rehospitalization ; Medicare ; hospital claims ; Medicare ; post-acute care transfer policy
heart failure ; refill compliance ; etidronate ; alendronate
metabolic exercise ; cardiac ; kidney index score
physique activity ; cRF ; HF mortality
ET ; HDl-mediated protective effects ; molecular pathways ; chronic heart failure ; chf
dopamine ; nesiritide ; renal
anemia ; iron deficiency ; MEDline ; cochrane Library
kccq ; HFpEF ; robbach
implantable cardioverter defibrillator-cRT ;LBBB

alendronate- etidronate ; raloxifene-treated
Chemotherapy ; trastuzumab ; CHF ; international Classification of Diseases ; Healthcare Common Procedure coding system codes
contemporary heart failure ;HF ; HF ; ventricular ejection fraction ;LVEF
hART ; HFpEF ; HF ; ejection fraction ;HFrEF
conscious dogs ; tachypacing-induced HF ; cXL ; contractility ; end-systolic elastance ; venoarterial dilation
bone morphogenetic protein ; expression ; rRNA transcription
actin cytoskeleton ; mitochondrial function ; metabolism ; glycolysis ;gluconeogenesis
resistin ; anthracycline-induced cardiotoxicity ; heart failure
extracellular matrix ; left ventricular biopsies ; tissueFAXs technologie
HF ; Danish Heart Failure database ; ESRD ; Danish Registry on Dialysis
ventricular assist devices ; lVADs ; heart failure ; pump dysfunction ; pump replacement
ST2 ; amino-terminal ; natriuretic peptide
biventricular pacing ; biVP ; cardiac output ; co ; cardiac surgery
magnetically levitated lVAS ; mortality ; Seattle Heart Failure
New York Heart association ;NYha ; chronic heart failure ; reduced ejection fraction
AlphaLISa immunoassas ; antibodies ; NT-probNP
creatinine ; bNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
expression ; mistargeting ; rad ; q66p ; RGK protein
Myocyte hypertrophy ; heart failure ; gene expression

biomedical treatment ; chm ; biomedical treatment ; dCM ; heart failure ; PubMed
sST2/high-dose BB ; sST2 ; b ; cardiovascular event
neurohormones ; adipokines ;cc ; progressive loss ; fat free mass ;FFm ; fat mass ;FM
cardiac plasma membrane ; s1PR1 ; deleterious β1AR overstimulation ; heart failure
Sprague-Dawley ; sham ; aCF ; allopurinol
myocardial collagen ; myocardial delayed enhancement imaging
saxagliptin ; sitagliptin
catheter ablation ; AF ; hfEF ; left ventricular ;LV ; ejection fraction
BB therapy ; sST2 ; chronic heart failure
ct ; hazard ratio
ESRD ; outpatients ; systolic HF ; egFR
passage ; length-force ; RV ; LV dysfunction
TUnel ; apoptotic cells ; TUnel-positive cells
hno ; myocardial function ; HF
rVADs
transitions ; readmission ; congestive heart failure ; Midwestern state ; South dakota
cardiomyocytes ; myocardium ; conditions ; stress
transplantation ; consultation
implantation ; LV assist device implantation ; heart failure
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation ; creatine kinase activity
correlation coefficient ; icc ; kappa coefficient ; change ; mdc
Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
Race ; heart failure ; Heart Failure ; controlled Trial Investigating outcomes ; Exercise TraiNing ;HF-ACtion
Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
heart failure ; preserved ejection fraction ; hff ; heart failure ; overweight
Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF
Renal dysfunction ; heart failure ;HF ; renal disease ; eRD
echocardiographic score ; LV ; reverse remodeling ; LV ; end-systolic volume
Peripheral artery disease ;PAD ; heart failure ;HF ; HF ;PAD
readmission rates ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
peripheral muscle pump ; cardiac filling ; subpulmonary ventricle ; Fontan circulation
biological phenotype ; medical records
SDQT ; HFVT ; hNorm ; β-adrenoceptor blockade ; esmolol
Cardiology practices ; national Cardiovascular Disease Registry practice Innovation ; Clinical Excellence
sts HH ; TM ; medical support ; all-cause mortality ; discharged patients ; heart failure
surgically induced myocardial infarction ; heart failure ; bisoprolol
transitions of care ; self-management ; out-patient follow-up ; health
CHF ; cardiac explant
tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; CHF-inv
hno donor ; cXL-1020) ; myoctyes ; intact hearts ; heart failure ;HF
drug-free
ms ; subvalvular ; dynamic ; annular MS ; fixed ring
race ; chronic heart failure ;HF ; exercise
histological analysis ; capillary ; coronary perfusion ; b-treated ; ad-flk ; b-treated ; ad-c
physician ; mortalité ; internists ; cardiologists
shuttle walk ; body mass ; hand grip strength
protocol-driven POc ;NP ; consultation ; ED ; throughput
heart failure ; CHARM programme ;Candesartan in Heart Failure ; Mortality
Troponin ; n-terminal pro-B-type natriuretic peptide ; biomarker ; heart failure ; atherosclerosis
left-to-right interatrial shunting ; heart failure ; ejection fraction
bmi ; weight ; heart rate ; rhythm ; lying ; standing blood pressure ; valvular disease ; pulmonary congestion
myocardial extracellular matrix ; cardiac magnetic resonance
aldosterone antagonist therapy ; heart failure ; post-myocardial infarction ; heart failure
Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin cardiotoxicity
heart failure ; left ventricular ejection ; spironolactone ; Kaiser Permanente Northern California
preoperative renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; coronary artery
MI ; septum ;systolic ; thickness ; LV ; posterior wall thickness ; LV ; interne diameter ; metoprolol
American College of Physicians ; aCP ; anemia ; iron deficiency ; heart disease
obese ; hfEF ; caloric restriction ; aerobic exercise ; VO2
économique Analysis ; Patient management ; Heart Failure Cost-Effectiveness Model ; coût-effectiveness ; disease management ; heart failure
HF registry ; HF ; EF ; HFpEF
BAT ; n-terminal pro-brain natriuretic peptide ; hz
HR variability ; AMI ; CHF ;LV dysfunction
cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
cardiac transplant ; ecc ; transplant pool ; transplant
Fontan ;PF
ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
Lancet ; anoop Shah ; air pollution ; heart failure
anemia ; HF ; health-related quality of life ; hQoL ; HF
cell therapy ; chronic heart failure ; chf ; explant-derived
mRI ; dyssynchronous nonfailing ;HF ; canine electromechanics ; remodeling
RV failure ; chronic pulmonary arterial hypertension ;pah ; acute pulmonary embolism
RV failure ; pulmonary embolism
serum resistin ; anthracycline-containing chemotherapy ; cardiotoxicity
sST2 ; cardiovascular
rad ; q66p ; cardiomyopathy ; channel-dependent
ventricular structure ; geometry ; fiber ;sheet orientation
SDQT-to-SDRR ratio ; HFVT ; HFVT ; hNorm
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; left ventricular ejection fractions
Exercise ; Medical Therapies ; Cardiac Function ; Shortness of Breath ; Lung congestion
electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; ventricular ejection fraction
tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol
cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs ; ejection fraction ;EF
Fractional flow reserve ; positron emission tomography ; ischemia ; bottleneck stenting ; left ventricle ;LAD
mitochondrial oxidative phosphorylation ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
spironolactone ; hyperkalemia ; acute kidney injury
mortality ; cardiovascular mortality ; h hospitalization ; cox
neprilysin inhibitors ; natriuretic peptide ; breakdown ; atrial natriuretic peptide
tAPse ; PASp ; nonsurvivors ; hFrEF ; HFpEF
HF-ACtion ; hf ; ejection fraction
histone acetyltransferases ;histone deacetylases ; cardiac development
NT-probNP ; mortality ; acute HF
Haematopoietic cell transplantation ; hCT ; congestive heart failure ; chf ; hCT ; anthracyclines
cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; doxorubicin
mir-25 ; cardiac dysfunction ; murine myocardium ; heart failure
Chinese herbal medicine ; chm ; dilated cardiomyopathy ; dm ; heart failure
hypertension ; hg ; diabetes mellitus ; diastolic murmurs
preoperative hypoalbuminemia ; albumin
electrical activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
patients ; advanced heart failure ;heart team ; cardiologists ; cardiovascular surgeons ; medical staff
Baroreflex sensitivity ; temps ; heart rate variability ; hv ; CHF-inv ; sham-inv ; sham-inv ; renal DNx
bisphosphonates ; alendronate ; etidronate ; heart failure
nurse ; cognitive impairment ; physician ; discharge ; elderly patients ; heart failure
carvedilol ; nonselective β-blocker ; β-blocker ; metoprolol ; thromboembolic events ; heart failure
cardiac transplant survival ; ECCT
HF ;AMI ; pna ; mortality
patients ; heart failure ;HF ; HF
remodeling ; arrhythmia substrate ;AMI ; HR variability ; arrhythmia events
doxorubicin-induced cardiotoxicity ; Hum-Retn mice ; littermate ; resistin
hypertension ; hfEF ; DASh ; RD ;target sodium
emd ; dyssynchronous HF
diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalities ; cardiovascular
ejection fraction ; cardiac index ; inotropes ; inotrope-dependent ; transplant
high-density lipoprotein ;HDl ; endothelial-protective effects ; endothelial cell ;EC ; nitric oxide
hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
degs ; non-ischemic ; ischemic heart failure ; heart failure
insulin resistance ; diabetes ; insulin receptor substrates ; irs1 ; iRS2 ; insulin-signaling
admission to discharge ; hospitalized older adults ; heart failure ;HF ; Nursing outcomes Classification ;NOc
8-fluo-cAMP binding ; phosphomimic Ser77 ; ser83 mutant ; RIα ; kd ; double mutant ; t RIα
preoperative albumin ; mortality ; implantation
systolic heart failure ; QRs ; cRT ; hospitalization ; heart failure
cox regression models ; propensity score decile ; glucocorticoid ; HF ; loop diuretics
fonctional electrical stimulation ; fes ; exercise ; emotional stress ; endothelial function ; heart failure ; impaired systolic function
dialysis ;HF
bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke
Beta blockers ; mortality ; readmissions ; heart failure ; ejection fraction ; hrEF ; heart rate ;HR
dyssynchronous HF ; electromechanical delay ; edd ; myocyte depolarization ; myofiber
QRs ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ;RAF
biomarker ; biomarker-guided clinical trial ; multimarker-based
SAF ; abnormal liver ; changes ; nodularity
transplant ineligible patients ; PD ; HF volume management ; pre-PD initiation
Frailty ; biological phenotype ; grip ; physical exhaustion ; weight
cRT-d ; IE ; IC ; cRT-d ; IEs
eds ; discharge ; heart failure ; ED ; readmissions ; repeat ED
acute right heart failure ; therapy refractory cardiogenic shock ; heart ; corporeal membrane oxygenation ; emo ; cPR ; ICU
right atrial myxoma ; massive embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
heart disease ; hf ; surgical palliation
heart magnetic resonance imaging ; chelation choices ; patient compliance ; heart failure ; arrhythmias
ejection fraction ;EF ; pre-PD ; NYha class IIIb ; right ventricular dysfunction
cPCs ; early-outgrowth colony-forming units ;EO-cFUs ; CD34 ; vEGFR2 ; CD133
expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
nitroxyl ; hno ; Angeli ; salt ; inotropic ; lusitropic ; vasodilator ; cAMP
anticoagulation ; cardiovascular complications ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
continuous-flow lVADs ; heartMate ; hm ; HeartWare ; bt ; dt
EF
skeletal muscle mass ; appendicular lean mass index
DASh ; mortality ; hf ; Mediterranean
Quality of life ; all-cause mortality
bNP ; bNP ; inhospital mortality
cardiovascular diseases ; heart failure ;HF ; HF
heart failure ; ventricular systolic dysfunction ; BB
CLCNka polymorphism ; heart failure ; glomerular filtration rate ; reNASTUR
ST2 ; functional capacity ; ambulatory patients ; HF
cardiac VEGF expression ; Akt ; endothelial NO synthase activation ; drug-untreated failing hearts
expression ; cardiomyocytes ; jq1 ; drug abrogated ; phenylephrine-induced genes
exercise-induced PASp ; right ventricular contractile reserve ; PASp
Gene expression ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure
cardiac insulin-resistance ; aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
DASh ; RD ; central blood pressure ; radial arterial tonometry ; cardiovascular ; echocardiographic
Psychosocial Factors ; Heart Failure Patients ; Heart Failure ; Exercise Training ;HF-ACtion
coronary angiography ; systolic HF ; unclear etiology
arterial elastance ; end-systolic elastance ; ventricular-arterial coupling ; techniques
rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device ; rhythm
angiotensin II ; angII ; hypoxia ; activateurs ; abnormal SCN5a mRNA splicing ; sCN5a
HF ; ejection fraction ;HFrEF ; HF ; ejection fraction ; hpEF
extracorporeal life support ; bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; endothelial function ; hpEF
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
intubation
raloxifene ; heart failure
hearts ;TTA ; tgtetMena mice ; wild-type littermates ; heart mass ; transgenic mice
hFrEF ; respiratory gas
drugs ; heart failure ; biomedical reasons
Wasting ; fat ; lean mass ; fat loss ; catabolism ; adipose tissue ; cardioprotective ; hf
hearts ; fish lacking ; nucleolin ; chamber patterning ; cardiac looping ; myocyte differentiation
black race ; HF ; exercise performance ; HF ; mortality ; exercise
acute myocardial infarction ; congestive heart failure
Macrophages ; cardiomyocytes ; Hum-Retn mice ; doxorubicin ; hRetn ; mRNA
lVADs ; CF devices ; HeartMate II devices ; Thoratec Corp ; Pleasanton ; Calif ; hVAD ; HeartWare intl ; Framingham ; Mass
FM ; plasma NPs ; adiponectin ; FM ; ff ; changes ; NPs ; adiponectin
sympathetic tone ; parasympathetic tone ; heart rate ; metoprolol ; atropine
EH ; HFpEF ; pathophysiologically ; HF ; hf ; hFrEF therapy
HF ; immunoreactive NT-probNP ; N- ; c-terminally truncated fragments ; NT-probNP
beat-to-beat QT interval ; surface eCGs ; atrial pacing ; esmolol ; isoprenaline ; atropine infusion

power spectral ; low-frequency ;high-frequency ;LF ;HF ; CHF-inv ; sham-inv ; sham ; DNx
contractility ; ventricular-arterial coupling ; SV ; ivabradine-treated
change ; hospital quality improvement
natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
cardiac magnetic resonance ; hfEF ; biomarker ; hfEF
HF-ACtion ; left ventricular ejection fraction ; New York Heart association ; HF
myocardial DD ; collagen deposition ; obese ; diabetic ZSF1 rats ; heart failure ; ejection fraction
cardiac tissue ; mice ; TAC- ; sham-operated ; jq1 ; BET ; cardiac gene expression programme
cox-proportional hazard models ; negative binomial regression models
Systolic blood pressure ; left ventricular ;LV ; hypertrophy ; AT ; AN ; AS ;ANS
conditional ; Hand2 mice ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene program
NT-probNP ; ED ; acute HF
Peak oxygen consumption ;VO2max ; HR
heart failure ; noncardiac ; cardiac transplant
frailty ; Health ABC Short Physical Performance Battery ; hABC Battery ; Gill index ; HF
epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; abrogate pathological gene expression ; HF
CAD ; angiography ; systolic HF ; coût
load-corrected chronotropic response ; heart rate
hospital ; gastrointestinal bleeding ; ventricular tachycardia storm ; terminal heart failure
catheter-based percutaneous revascularization ; angioplasty ; stenting
HF ; t2d ; ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm
HF ; QRs prolongation ; LVEF ; crte ; reverse remodeling ; LV
RV ; lVAD ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure

non-frail ; Gill ; HF
HF ;AMI ; odds ratio
Chronic heart failure ; chf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
β-AR ; catecholamine infusions ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac β-AR responsiveness
pAH ; RV decompensation ; RV failure management ; pAH
zSF1 ; heart failure ; ejection fraction ; lung weight ; ventricular ejection fraction ; left ventricular DD
Xanthine oxidase ;XO ; rat ; ventricular ;LV ; myocytes ;VO ; mitral regurgitation ; aortocaval fistula ; acf
free-breathing pulse sequence ; myocardial t1 changes ; swine ; tachycardia-induced heart failure
pf ; New York Heart association
comanagement ; medication
high-volume physicians ; mortality ; low-volume physicians ; low-volume hospitals
Western Australian ; administrative health ; hf ; AMI
conditions ; Turkey
eds ; responsable diagnosis ; heart failure ; ed
nursing-sensitive outcomes ; science ; treatment ; older adults ;HF ; nursing
miRNAs ; RNAs ; expression ; binding ; messenger RNA ; degradation ; translational repression
hpEF ; ivabradine
Cardiac ; cardiac ; explant-derived cells ; cardiac functions ; myocardial infarction
NPs ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
pathophysiology ; hf ; medical management ; pathophysiologic
heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pna
mortality ; healthcare utilization ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
jq1 ; BETs ; chromatin ; RNA polymerase II
catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hff
heart failure ; preserved ejection fraction ; hpEF
cox proportional hazards ; ie ; acute coronary syndromes ; coronary interventions
adenosine monophosphate ; cAMP ; cyclic guanosine monophosphate ; cgmp ; failing hearts
RA ; methotrexate ; tNF antagonist ; non-biological disease modifying antirheumatic drug ; nbDMARD
intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic/anabolic imbalance ; cardiac cachexia ; CHF
ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
sphingosine-1-phosphate receptor ; s1PR ; β1-adrenergic receptor ; gr-protein-coupled receptors ; heart
septal ; PCWP
atrial fibrillation ; carvedilol ; metoprolol
Bradycardia ; metoprolol ; cardiac sympathetic tone ; CHF-inv rabbits ; sham-inv ; CHF-DNx
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
cPG-recommended pharmacological treatment ; ventricular
grs ; LVEF ; sa ; CV ; echocardiographic systolic parameters ; AF
ERC ; DAPc ; sarcomeric microstructure ; Skm ; myofibre regeneration
signalling cascades ; microRNAs ; bHLh transcription factor ; Hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
rad ; q66p ; inhibitory actions ; rad ; cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
EF ; LCx ; LAD ; stenting ; infarcted left ventricle ; LCx ; LAD
EH ; LV compliance ; kv ; LV ; end-diastolic volume ; LV ; end-diastolic pressure ; hg ; coefficient
mva ; implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
hART ; New York Heart association ;NYha ; HF ; self-management counseling ; death ; HF
cardiac function ; echocardiography ; diastolic dysfunction ; ejection fraction
BET family bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF ; HF
transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
grade
HF
right heart circulatory failure ; disease ; right heart
voltage-gated ; ventricular action ; excitation-contraction ;EC ; coupling ; myocardium
ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; preserved ejection fraction ; hpEF
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
bNP ; glomerular filtration rate ; hypertension ; transmitral e-wave ; diastolic mitral annular velocity
AT1 receptors ; neprilysin blocks renin-angiotensin-aldosteron ;RAS ; vasodilatory ; diuretic
β-blockade ; cAMP-dependent protein kinase ; pKA ; β-adrenergic receptor activation
erythropoiesis-stimulating agent therapy ; benefits ; venous thromboembolism
black race ; mortality ;hazard ratio ; cardiovascular mortality ;HF
chronic myocardial ischemia ; stent ; polytetrafluoroethylene tube
clinical ; genetic ; CHF
oxygen uptake ; metabolic exercise ; cardiac ; kidney ; hz
heart failure ;HF ; tumor necrosis factor ;TNf ; tNF ; HF
Centers for Medicare and Medicaid services ; cms ; mortality ; readmission rates ; penalties
temps-dependent ; follow-up ; physician ; discharge ; death ; readmission
figure ; CAD ; diameter stenosis ; figure ; CAD ; angle de descending artery
signal transduction cascade ; transcription factors ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin structure
hff ; sodium-restricted DASh ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; ventricular dilatation
Randomized aldactone Evaluation Study ; chronic advanced heart failure ; aldosterone antagonist ; spironolactone
heart failure ; acute myocardial infarction ; acute myocardial infarction ; Western Australia
CHF ; hCT ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
medication
pathophysiological
lVAD ; albumin ; hypoalbuminemia
creatinine ; dl ; post-transplant mortality
glomerular filtration
hm ; HeartWare ; économique evaluations ; hm
dopamine ; nesiritide ; renal function ; acute heart failure ; renal dysfunction
HR variability/turbulence ; HR variability/turbulence ; cardiac
implantation ; lVAD therapy ; transplantation eligibility status ; device ; bt ; dt ; medical therapy
radial artery tonometry ; PH ; ICU
magnetically levitated centrifugal-flow chronic lVAS
eRK ; signalling ; signalosome complex ; scaffold protein ; kinases ; sequential phosphorylation
breast cancer ; Medicare coverage ; stage I-III breast cancer ; chemotherapy ; sEER-Medicare ; Texas Cancer Registry-Medicare
ejection fraction ; natriuretic peptide ; heart failure ; guideline-Heart Failure Registry
cardiomyocytes ; pde2 activity ; cgMP ; nitric oxide ; pde2 ; β-AR responsiveness
l-dKO ; cardiac ; iRS1 ; iRS2 ; heart failure ; impaired cardiac energy metabolism ; mitogen-activated protein kinase
ECs ; HDl ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-βII-Ser ; p70s6K-Ser
PASp
rCTs ; sts ; hm ; tm ; sts ; tm
mouse ventricular myocytes ; sarcomere
administrative databases ; province of Alberta ; discharged alive ; hospital ; heart failure
heart failure ; myocardial collagen ; tissue ; heart failure
ct ; temps ; hf ; LVEF
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR1 cardiac gene therapy
RR ; heart failure ; bisphophonates ; crude RR ; confidence interval ; hazard ratio
high-cost Medicare fee-for-service beneficiaries ; Centers for Medicare ; Medicaid services
physician adherence ; guideline recommendations ; heart failure ; Clinical practice Guideline ; cg ; heart failure ;HF
nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; antitumor activity
kccq ; New York Heart association class ; HFpEF ; HF ; EF
Rhythm control therapy ; af ; atrial structure ; rhythm ; delayed rhythm control ; rate control
acute heart failure ; renal dysfunction ; dopamine ; nesiritide ; renal function ; diuretic therapy
HF ; body composition ;skinfold thickness ; dual-energy X-ray absorptiometry ; echocardiography ; blood testing
heart failure
aCP ; restrictive red blood cell transfusion ; hemoglobin ; hemoglobin ; coronary heart disease
hospitals ; heart failure ;HF ; conditions ; acute myocardial infarction ; pneumonia ; conditions
implanted left-to-right interatrial shunt ; haemodynamic outcomes ; heart failure ; ejection fraction
ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
ventricular assist devices ; lVADs ; chronic end-stage heart failure ; bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy ; dt
Caloric restriction ; Aerobic Exercise ; Peak oxygen Consumption ; Heart Failure ; ejection Fraction
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADit-crte ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
Oral glucocorticoids ; HF
HR ; ivabradine group ; Ea ; TAC
carvedilol ; metoprolol
chm ; adjunctive treatment ; dCM ; heart failure
testosterone ; exercise rehabilitation ; CHF ; low testosterone status
VO2 ; change ; lean body mass ; change ; thigh ; intermuscular fat ratio
guidelines-Heart Failure ; hf
économique Analysis ; Patient management ; Heart Failure Cost-Effectiveness Model ; long-term cost-effectiveness ; disease management ; heart failure
HFPSI ; death ; medical hospitalization ; HF ; HF ; HF resources ; health systems
cardiac insulin-restance ; mitochondrial oxidative metabolism ; metabolic changes ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
cox model ; PASp ; exercise ; PASp
pathophysiology ; heart failure ; preserved ejection fraction ; hff ; myocardial extracellular matrix accumulation
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular ;LV
breathing control ; cardiac arrest ; pulseless ventricular fibrillation ;PVf ; implanted cardioverter-defibrillator device
rad ; rGK ; rem ; rem2 ; rad ; Gem ;Kir ; monomeric g proteins ; ventricular action ; EC coupling gain ; cardiac
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; hz ; myocardial infarction
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; β-blocker
Swedish Web-system ; evidence-based care ; Heart disease ; caBG
LVEF ; reverse remodeling parameters ; temps ; hh
brain natriuretic peptide ; bNP ; bNP ; bNP ; bNP ; bNP
coprimary end points ; cumulative urine volume ; decongestion ; change ; serum cystatin c ; enrollment ;renal function
tAPse ;longitudinal RV fiber shortening ; PASp ;force ; RV ; in vivo ; RV ; length-force
pde superfamily ; pde2 ; cgmp ; cAMP hydrolysis ; cgmp ; cAMP
n-terminal proBNP ;NT-probNP ; midregional proANp ;MR-proanp ; adiponectin ; CHF ; bmi ; FM
re-hospitalization ; admissions
mitochondrial-targeted antioxidant ; Szeto-Schiller ;SS ; SS20 ; cardiac function ; proteomic remodeling
financiers ; cardiac arrest ; cardiopulmonary resuscitation ; cPR ; posterior wall infarction ; cardiac centre
hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor ; heart failure ;HF
aCP ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; long-acting insulin
uPR ; sCN5a ; ventricular systolic HF ; implanted pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
ambulatory patients ; heart failure ;HF ; ejection fraction ;rEF ; renin-angiotensin system ;RAS ; β-blockers
décision-support ; financial incentives ; cochrane Effective practice ; organisation of Care Taxonomy
coPD ; CHF ; cRF ; icc ; kappa
heart failure ; left ventricular ejection fraction ; aerobic training ; dynamic resistance training ; lower limbs
implantable cardioverter-defibrillator deactivation ; implant ; end-of-life
heart failure ; myocardial function ; ventricles
implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator shocks
left ventricular longitudinal systolic strain ; grs ; left ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ;AF
mouse ; rad ; murine ; rad ; kv ; currents ; cav ; rad
MI ; early-onset HF
Medicare ; patients ; acute care hospital ; hz ;AMI ; pna
cardiovascular events ; sST2 status ; metoprolol succinate
ctnt ; NT-probNP ; aRIC HF model ; aucs ; continuous NRIs
early-onset ; HF ; HF ; EF ; HF ; EF ; HF ; HF ; HF ; MI
EC ; HDl ;NYha-IIIb ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDl
carvedilol ; Willebrand ; metoprolol ; β2-adrenergic receptor haplotype
mouse heart failure ;HF ; hypertensive heart disease ; hd ; pathophysiology ; hd
sarcoplasmic reticular ;SR ; protein ; SR ; ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
Timed up & Go ; tug ; advanced chronic obstructive pulmonary disease ; coPD ; chronic heart failure ; chf ; chronic renal failure ; cf
entramuscular testosterone ; chronic heart failure ; chf ; low testosterone
HF ; LVEF ; long-term mortality ; LVEF ; LVEF ; long-term mortality
grs ; left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; CV
heart failure ;HF ; plasma ; b-type natriuretic peptide ; bNP ; ejection fraction ;EF ; HF
RM ; home telemonitoring ;TM ; implanted monitoring devices ; medical support ; telephone support ; sts ; contact ;HH ; human-to-machine interface ;HM
temps-dependent cox regression ; beta-blockers ; beta-blockers ; antitachycardia pacing ; aTP ; shock therapy
ethically complex situations ; pediatrics ; families ; religious beliefs ; life-sustaining treatment ; légal majority ; decisions
medications ; medical records
coût ; rhythm-control ; rate-control
ventricular ejection fraction ; egFR
fit ; unfit ; cRF distribution ; fit ; unfit ; overweight ; body mass index ; obese
ct ; hazard ratio
HFPSI ; blood urea nitrogen ; natriuretic peptide ; New York Heart association class ; diabetes ; atrial fibrillation
Medicare Patient Safety Monitoring system ; mpSMS ; acute myocardial infarction ; congestive heart failure ; pneumonia ; surgery
CD34 ;vegFR2 ; functional capacity ; CD34 ; avf2 ; VO2
heart failure ; ejection fraction
figure-fatality ; HF ; HF
CHF ; anthracycline ; stem cell
tension ; fréquence ; muscle strips ; kcl-KI ; titin ; extracellular matrix ; Fpassive
reversibility ; heart failure ; myocardial infarction ;MI ; β-adrenoceptor blockade ; infarcted rats ; metoprolol
aerobic ; resistance ; exercise capacity ; muscle strength ; cardiac ;NT-probNP ; inflammatory ; i6 ; hsCRp
readmission ; all-cause readmission ; aCR ; Potential Preventable Readmission ; pPR ; Centers for Medicare ; Medicaid ; cms
congestive heart failure ; ed

arginine vasopressin ; aVP ; physiologic processes ; CHF ; aVP ; vasopressin receptor antagonist therapy ; CHF
angiotensin-converting enzyme inhibiteurs ;angiotensin receptor blockers ; β-blockers ; heart failure ; ejection fraction
implantable defibrillateurs ; circulatory support ; transplantation ; heart failure
hypertension ;DASh ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive hfEF
ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; RTq-PCr ; interventricular septum biopsies ; beagle dogs ; heart failure
Rats ; hearts ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome ; bcl2 ; Bax ; caspase
metoprolol ; carvedilol ; sympathetic activity ; Willebrand factor
acute HF ; RELAx-aHF ; ASTRONAUT ; prONTO
Hospitalized HF ; international Classification of Diseases ; Clinical Modification codes ; principal discharge
Pulmonary capillary wedge pressure ; hg ; hg ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
rad ; q65p ; mouvement ; wild-type rad ; q65p ; l-type channel inhibition ; RGK proteins
SS20 ; heart failure ; proteomics changes ; actin cytoskeleton ; SS20 ; mitochondrial ; metabolic pathways
New-onset aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; ventricular dysfunction ; HF
discharge
life expectancy ; heart failure ; refractory ; terminal heart failure
heart failure discharges ; University of Connecticut Health Center
New York Heart association ;NYha ; class II Heart Failure ; eplerenone ; Heart Failure Medicines ;EMPhaSIS-HF
echocardiograms ; left ventricular base ; midpapillary ; IVc ; BiVP ; ste ; twist ; basal rotations ; CS ; RS
drugs ; RAas ; direct renin inhibitors ; endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic studies ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
hf ; phenylephrine ; haemodynamic stress ; transverse aortic constriction ; jq1 ; cardiac hypertrophy
Muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan
i-mig cardiac washout ; carvedilol ; metoprolol ; β2-adrenergic receptor haplotype
acute myocardial infarction ;AMI ; heart failure ;HF ; complicating AMI
h-dKO ; ventricular mass ; cardiac apoptosis ; fibrosis ; action ; forkhead box ; impaired cardiac metabolic gene expression ; ATP
bottleneck stent ; implanted ; left anterior descending ;LAD ; proximal circumflex artery ;LCx ; proximal LCx ; la
postmarketing ; hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dp-4 ; antihyperglycemic agents
quality improvement ; multivariable cox modeling ; Heart Failure Patient Severity index ; hPSI ; University of Michigan ; hf ; ml
pde2 ; cardiomyocytes ; cAMP ; ca2 ; inotropic effect ; β-AR ; basal contractility
ATP ; shock therapy
Cardiac resynchronization therapy ; ct ; dialysis-dependent patients ; heart failure ;HF ; ct ; dialysis
cardiorespiratory fitness ; crf ; body mass index ; heart failure ;HF ; cardiovascular risk factors ; HF mortality
eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone ; hospitalization ; survIval Study in Heart Failure
Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ; chf ; left ventricular ;LV
neonatal rat ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; cardiac dysfunction ; insulin resistance ; diabetes
echocardiograms ; left ventricular midpapillary ; atrioventricular delay ; avd ; interventricular delay ;VVd ; ste ; circumferential strain ;CS ; radial strain ;RS
New York Heart association ;NYha ; functional class III HF ; ejection fractions ; chronic guideline-directed medical therapy ;GDMT
non-LBBB ; QRs ; ms ; ms
dyssynchronous HF ; myofiber ; septum ; myofiber shortening ; stretch rate ; late-activated lateral wall
label-free shotgun proteomics ; global proteomics changes ; transverse aortic constriction ;TAC ; heart failure
CHF ; transforming growth factor-β ; tGF-β ; epithelial ; mesenchymal transition markers ; pluripotency markers ; shams
pka ; regulatory ;RIiα ; catalytic ; cα ; rIIα ; ser96) ; cα ; phosphorylation ; hz
hFrEF ; left ventricular ejection fraction ; hfpEF ; left ventricular ejection fraction ; RAS- ; β-blocker ; HF
g-protein-coupled receptors ; reciprocal regulation ; mouse hearts ; β-adrenergic receptor ; rat ; postischemic heart failure
concentric remodeling ;CR ; concentric hypertrophy ;CH ; left ventricular ;LV ; remodeling ; heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
weight
RV dysfunction ; confidence interval ; cachexia
resting HR ; VO2max ; lower resting HR
tGF-β inhibition ; c-Kit ; cardiac progenitor
NT-probNP ; inflammatory biomarkers ; hsCRp ; il6 ; hsCRp
BETs ; neurohormonally induced heart disease ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; pro-brain natriuretic peptide ; heart failure ; GDMT-treated NYHA ; HF
p70s6 ; PKc-βII ; HDl ; malondialdehyde ; HDl ;NYha-IIIb
mlf ; exercise ; diet
nonpace ; non-DNx ;ham-Innervated ; ham-inv ; nonpace DNx ; hz-DNx ; pace non-DNx ; chf-inv ; pace ; DNx ; chf-DNx
hABC Battery ; HF ; Health ABC HF Model ; SD ; death
ejection fraction ; frail ; biological phenotype ; frailty ; deficit index
hemoglobin ; hgb ; HRQoL ; HRQoL ; Heart Failure ; Exercise Training ;HF-ACtion
atrial Fibrillation ; congestive Heart Failure ; expenditures ; Québec ; rhythm ; rate-control treatment ; single-payer ; coût-minimization
heart failure ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; renal dysfunction
calcineurin ; nfat ; miR-25 expression ; helix-loop-helix ; bHLh ; transcription factor dHAND ; Hand ; mouse ; myocardium
PSs ; btes ; exercise time ; PSSS ; btes
NT-probNP
prognostic power ; r-R interval ; HR ; short-term fractal scaling
diastolic filling ; relaxation ;viscoelastic ; doppler mitral inflow ; e-wave
heart failure ;HF ; ventricular tachycardia ; hVT ; hVT ; VT ; structurally normal hearts ; hNorm
grs ; cox model ; chronic heart failure ; hypertension ; diabetes ; stroke ; glomerular filtration rate ; LVEF ; CV
VAD ; ventricular assist device ; ECmo ; extracorporeal membrane oxygenation membrane ; ECmo ; VAD
ischemic events ;IEs ; ischemic cardiomyopathy ;IC ; cardiac resynchronization therapy ; defibrillator ; ct-d
coût-effectiveness ; heart failure disease management
resistin ; heart failure ; mouse ; murine resistin ; Retn gene ; hum-retn mice ; basal ; inflammation-stimulated resistin
angiotensin-converting enzyme inhibiteurs ;angiotensin receptors ; blockers ; β-blockers
ttt ; mice ; cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ; implantable cardioverter defibrillator-cRT ; mortality ; heart failure
heart failure ; Italy ; cfa ; SCHFI ;Self-Care Maintenance ; Self-Care management ; Self-Care Confidence
mwt ; NYha ; HFpEF ; hFrEF ; HFpEF ; HFpEF ; hf
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy
Raf-MEK1/2-erk1/2 scaffold proteins ; cardiac remodelling
CHF ; SD ; testosterone
functional MS ; LV dilatation ; treatment for heart failure ;HF ; LV ; functional MS ; HF ; MR ; prolapse ; degenerative mitral valve
New York Heart association ; kccq ; HF ; EF ; HFpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; heart failure ; medications
c57BL ; ANG ; infusion ; uninephrectomy ; ANG ; infusion ; salt loading ; ANG ; infusion ; uninephrectomy ; salt loading
early transmitral blood flow ; doppler ; early diastolic mitral annulus ; pulmonary capillary wedge pressure ;PCWP ; decompensated systolic heart failure ;HF
LV ; ejection fraction ; LV ; strain ; systole ; diastolic indices ; LV ; strain rate ; diastole ; early transmitral flow ; sinus rhythm
VO2 ; exercise ; body mass
age- ; sex-adjusted risk ; early-onset HF ; hh
AMI ; hospital ; odds ; dying
Mass spectrometry ; n- ; c-terminally processed forms ; circulating NT-probNP ; physiological proteolysis
ctnt ; NT-probNP ; ctnt ; NT-probNP ; HF
HFpEF ; New York Heart association ; mean ejection fraction ; fees
depressed left ventricular ;LV ; pressure ; pressure ; ejection fraction ; fractional shortening ; cardiac output ; LV ; end-diastolic pressure ; MI ; metoprolol
baroreflex Activation Therapy ; Heart Failure ; Reduced ejection Fraction ; carotid ; baroreflex activation therapy ;BAT ; advanced heart failure ;HF
enrollment
hf ; raised blood glucose ; obesity ; tobacco ; aging ; systemic hypertension ;SH ; rheumatic fever ; Chagas ; disease ; la
cRF ; normal ; overweight ; obese body mass index
kccq ; HFpEF ;log ; ef
egFR ; egFR ; egFR ; uncontrolled hypertension ; diuretics ; temps ; ESRD
myocardial phosphodiesterase-2 ; pde2 ; heart failure ;HF ; pde2 ; beta-adrenergic receptor ;β-AR ; cardiomyocytes
heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
ERC ; epicatechin-rich cocoa ; Skm mitochondrial structure ; rob ; ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; maisel ; Henry
follow-up ; death ; urgent readmission
mena overexpression ; TTA ; mice ; TAC surgery ; cardiac hypertrophy ; TTA ; TAC ; cardiac functional deterioration
echocardiography ; LV ; end-diastolic volume ; MR ; mitral valve opening ; mva ; pressure gradient ; hg
p ; diuretic refractory severe-end-stage HF ; prelated complications
ATP ; aac ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium ; hyperkalemia ; medication
New York Heart association class III heart failure ;HF ; ventricular ejection fraction ; permanent periodic breathing ;PB
implantation ; bottleneck stent ; proximal LAD ; LCx ; reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
potassium ; spironolactone ; AAs ; race by treatment
obese ;SD ; body mass index ; hFPEF
proangiogenic effects ; b ; VEGF pathway ; adenoviral vector ; decoy ; VEGF receptor ; ad-flk ; adenovirus ; ad-c
surgery ; post- lVAD ; aortic valve oversewing ; leaflet repair ; bioprosthetic aortic valve replacement ; CF lVAD ; AI
exercise-induced pulmonary artery systolic pressure ;PASp ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
MEDline ;EMBAse ; HEalthSTAR ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs Institute evidence Based practice
VA health care systems ; systolic heart failure ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibiteurs ;angiotensin receptor blockers ; angiotensin converting enzyme inhibiteurs intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
open chest model ; twist ; RS ; RS synchrony ; CS ; ste ; changes ; CO ;RVPO ; RS synchrony ; CS ; BiVP ; CO
tAPse ; PASp ; tAPse-to-PASp ratio ;TAPSe ;PASp ; cox regression ; Kaplan-meier ; tAPse ; PASp
cPET ; CHF ; exercise ; exercise ; rehabilitation
Human heart failure ;HF ; mRNA splicing ; v ; voltage-gated cardiac ; na+ channel ; truncated ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; heart failure ; anthracycline ; childhood malignant disease
économique Analysis ; Patient management ; Heart Failure Cost-Effectiveness Model ; medications ; costs
natriuretic peptides ;NPs ; b-type NP ; n-terminal pro-B-type NP ; acute heart failure ; Emergency Department ; ed ; acute dyspnea
oxygen consumption ; VO2 ;ven ; vco2 slope ; oscillatory ventilation ; eOV ; pressure ; end-tidal CO2 ;PETco2 ; cardiopulmonary exercise
Denmark ; bisphosphonates ; raloxifene
hypertension ; LV dilatation ; LV dysfunction ; MR ; MS ; mitral valve ; closure ; lesion ; systolic ; diastolic tethering ; MR ; MS
tolvaptan ; hyponatremia ; japon ; congestive heart failure ; diuretic therapy ; serum sodium
longitudinal strain ; left ventricle ; echocardiographic measurements ; baseline echocardiography ; ct ; echocardiograms
platelet-activating factor ;paf ; metabolic enzymes ; heart failure ; hz ; bmi
acute care surgery ; acs ; oHT ; transplantation ; m ; intravenous inotropes ; ventricular assist devices ;VADs
hpEF ; ivabradine ; ventricular ; filling pressure ; exercise ; early diastolic mitral flow ; diastolic mitral annular velocity
renin-angiotensin-aldosterone system ;raas ; hFrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; HFpEF
admission ; lVET ; tonometric indices
heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; β-blockers
cardiac performance ; β-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump ; reverse cardiac remodeling ; plasma catecholamines
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers therapy ; β-blockers therapy
SS ; congestive heart failure ; mitochondrial damage ;TAC ; mitochondrial proteome changes ; mitochondrial ; nonmitochondrial protein changes
depressed myofibrillar ca(2+)-stimulated ATPase activity ; mRNA ; ca(2+)-pump ; phospholamban ; α-myosin heavy chain ; mRNA ; β-myosin heavy chain ; metoprolol
HDl ; healthy controls ;HDl ; CHF-NYha-III ;HDl ; et ; CHF-NYha-II ;HDl ;NYha-IIIb
anesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
md ; md ; mdc ; mdc ; mdc ; mdc
baseline ; heart failure ; t1-mapping ; administration ; contrast agent ; ms ; administration ; ms
hf ; la ; idiopathic dilated cardiomyopathy ; cd ; ischemic ; SH ; valvular ; alcohol
ST2 ; functional capacity ; ambulatory patients ; HF ; Heart Failure ; Exercise Training ;HF-ACtion ; exercise training ; HF
cardiopulmonary exercise ; exercise rehabilitation ; patients ; chronic heart failure ; chf ; CardioPulmonary Exercise Testing ; cPET ; exercise rehabilitation ; China
AA ; ischemic HF ; NYha functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
HF-ACtion ; HF ; ventricular ejection fractions ; HRQoL ; Kansas City Cardiomyopathy Questionnaire ; kccq
ct ; systolic dysfunction ; resynchronization reVErses remodeling ; Systolic left v entricular dysfunction ; left ventricular ;LV ; ejection fraction ;LVEF
glomerular filtration rate ; egFR ; diabetes ; cholesterol ; lDL-cholesterol ; CLCNKA GG
echocardiography ; LV ; end-diastolic dimension ; LV ; end-diastolic pressure ;wall stress ; lung weight ; aCF ; sham
aUC
spironolactone
Rate-control ; cardiac procedures ; cardioversions ; coût ; antiarrhythmic drugs
diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone ; post myocardial infarction ; Heart failure Efficacy ; survival Study ; epeleSUS ; post-myocardial infarction ; heart failure ; mortality ; aldosterone antagonist eplerenone
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADt-crte ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
heart failure-related mortality ; sudden death
DASh ; sd ; brachial systolic pressure ; central end-systolic pressure ; hg
hf ; obese ; body mass index ; black ethnicity ; idiopathic-dilated cardiomyopathy
all-cause mortality ; HF ; LVEF ; Heart Failure Survey ; ISrael
ventricular ejection fraction ; World Health Organization ; idiopathic dilated cardiomyopathy ; negative coronary angiography
european Society of Cardiology ; hff ; heart failure ; ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ; inimpaired LV relaxation ; LV ; diastolic stiffness ; LV ; filling pressures
β1ARs ; s1PR1s ; myocyte ; cAMP production ; receptors ; regulatory involvement ; g-protein-coupled receptor kinase
PAf-cp ; PAf ; lyso-paf-AT ; PAf-AH ; lp-PLA2
heart failure ; ejection fraction ; cardiac rehabilitation ; Nordic walking
ds-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
skeletal ; muscle mass ; t-score ; sarcopenic range ; muscle wasting ; t-score
testosterone ; oxygen uptake ; Beck depression inventory ; leg strength ; Medical Outcomes ; Short-Form quality of life
RAS ; β-blocker uptitrations ; all-cause mortality ; hf ; hf ; hf
Heart Failure ; controlled Trial Investigating outcomes of Exercise Training ;HF-ACtion ; social support ; barriers to exercise ; social support score ;PSs ; barriers to exercise ; btes
ST2 ; cardiovascular death ; hz ; all-cause mortality
New York Heart association ; cardiopulmonary exercise ; lean mass ; x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
dopamine ; nesiritide ; diuretic therapy ; renal ; acute heart failure ; renal dysfunction
ct ; New York Heart association ; heart failure ; left ventricular ejection ; QRs ; echocardiographic ; left ventricular dyssynchrony
left ventricular ;LV ; ejection fraction ; hf ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow ; mitral annulus ; diastole
acute coronary syndromes ; CAD ; bNP ; NT-proBNP ; CAD
hf ; lyso-paf-AT ; PAf-cp ; PAf ; PAf-AH ; lp-PLA2
medical therapy ; redo sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve ; open surgery ; aortic valve replacement
cutoff ; plasma ; n-terminal pro-B-type natriuretic peptide ;NT-probNP ; acute heart failure ;HF ; emergency department ; ed
cardiac troponin t ; ctnt ; n-terminal pro-B-type natriuretic peptide ;NT-probNP ; HF ; HF ; HF ; Atherosclerosis Risk in communautés ;ARIc
body mass index ;HR ; fat mass ; fat-free mass index
COPd ; CHF ; cRF
reverse remodeling ; ejection fraction ; mortality ; hh ; dialysis
EH ; LV contractility ; LVEF ; ratio of systolic blood pressure ; end-systolic volume ; hg
echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; MS ; mva ; pressure gradient ; hg
implantation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration
BETs ; chromatin-mediated signal transduction ; Pol II ; co-activating transcription factor réseaus ; hf ; nucléaire factor ; activated T cells ; nFAT ; nucléaire factor-κb ;NF-κb ; transcription factor
mortality ; cardiovascular events ; myocardial infarction ; congestive heart failure ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
all-cause ; cardiovascular mortality
EO-cFUs ; diabetes ; diabetes ; e-cFU ; VO2 ; diabetes ; EO-cFUs ; VO2
immunoblotting ; radioenzymatic- ; fluorescence resonance energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; ca2 ; myocardial tissues ; cardiomyocytes ; hz
eAST ; atrial fibrillation ; Stroke prevention Trial ; AF ; stroke ;CHA2DS2VASc ; rhythm control therapy
Exercise capacity ; oxygen consumption ;VO2 ; QOL ; Minnesota Living with Heart Failure ; mlf ; heart failure-related QOL
TAC-induced proteomic alterations ; mitochondrial-targeted peptide ; SS31 ; mitochondrial function ; pathway alterations ; TAC ; mitochondrial-targeted peptide drugs ; heart failure
ventricular ejection fraction ; hf ; ventricular ejection fraction ; hospital ; acute ; outpatient settings ; financier costs
hf ; left ventricular ;LV ; ejection fraction ;HFpEF ; echo-Doppler studies ; pro-brain-type natriuretic peptide
low-volume EDs ; hospitalized ; high-volume EDs
cardiac transplant ; ECCT ; diabetes mellitus ; chronic kidney disease ; glomerular filtration
hABC Battery scores ; Health ABC HF Risk Model ; discrimination ; c-index ;net-reclassification-improvement ; HF
cf ; RMsea ; Self-Care Maintenance Scale ; cf ; RMsea ; Self-Care management Scale ; cf ; RMsea ; Self-Care management Scale ; cf ; Self-care confidence
BAT ; distance walked ; quality-of-life score ; NYha functional class ranking
hypoalbuminemia ; albumin ; hypoalbuminemia ; albumin ; lVAD
rehospitalization ; acute myocardial infarction ;AMI ; kidney infection ; urinary tract infection ;UTI
patients ; heart failure ;HF ; ischemic ; cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; ventricular assist devices
SAF ;PF ; catheterization ; central venous pressure ; hg ; sVR ; dyn ; cardiac
admission ; median bNP ; EF ; EF ; bNP ; EF
heart failure admission ; heart transplantation ;LV assist device ; death
LV ejection fraction ; vitesse de circumferential shortening ; elastance ; contractile efficiency ; aCF ; aCF ; allopurinol rats ; o2 consumption rate ; cardiomyocytes ; extracellular flux
hpEF ; LV ; normal geometry ; LV hypertrophy ; LVh ; relative wall thickness ;RWt ; cr ; LVh ; rWT ; vh ; WT ; EH ; LVh ; WT
lCZ696 ; angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; ejection fraction ; heart failure ; ejection fraction
blood pressure ; mitral valve plasty ; degenerative MR ; prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio Ring ; edwards Lifesciences ; irvine
shuttle walk ; oxygen uptake ; muscular strength ; echocardiographic measures ; pro-brain natriuretic peptide ; depression ; beck depression inventory ; minnesota Living with Heart Failure Questionnaire ; Medical
LVEF ; long-term mortality ; LVEF ; age-by-LVEF
Wistar-Kyoto ; lean ZSF ; obese ZSF1 ; zSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic ; hemodynamically
Kaplan-meier curves ; log-rank ; risk stratification ; UM/va/va-RT
af ; long-standing persistent AF ; hypertension ; sinus rhythm ;hazard ratio
HF-ref ; NYha functional class II ; egFR ; potassium ; eplerenone ; hyperkalemia ; wRF
ff ; FM ; body fat distribution ; dual energy X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ; chf ;cc ; CHF ; myocardial infarction-both
drug dose ; spironolactone ; end point of death ; hh ; AAs ; AAs
pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; impaired right ventricular pump ; pulmonary arterial hypertension ; medication ; stress echocardiography ; cardiopulmonary exercise
cardiovascular death ; HF ; btes ; btes ; cardiovascular death ; HF
index ED ; low-volume ED ; death ; readmission ; aOR ; high-volume EDs
implantable cardioverter-defibrillator deactivation ; implantation ; implantation ; implantable cardioverter-defibrillator deactivation
Cardiac magnetic resonance ; left atrial ; pulmonary vascular resistance ; cardiac events
HF ; systolic ; left ventricular ejection fraction ; HF ; conditions ; New York Heart association ; echocardiographic ; cardiopulmonary exercise
heart failure ; ABCd ; American College of Cardiology ; acc ;American Heart association ;AHA ; New York Heart association ;NYha ; structural heart disease ; heart failure
mva ; continuity equation ;LV ; end-diastolic volume ; LV ; end-systolic volume ; mitral filling flow ; mva ; temps ; mitral filling flow ; continuous wave doppler echocardiography ; MR ; mitral valve plasty
RM ; all-cause mortality ; sts HH ; crI ; TM ; office hours ; crI
HFPSI ; Ann Arbor Veterans' Affairs ; HF clinic ;VA ; HFPSI ; VA-RT ; VA ; HFPSI ; HFPSI
AAs ; spironolactone ; hyperkalemia ; potassium ; hypokalemia
LVEF ; long-term mortality ; LVEF ; LVEF ; LVEF
hpEF ; heiha ; NYha ; distance ; walk test ; mwt ; medications
echo-derived pulmonary arterial systolic pressure ;PASp ; right ventricular ;RV ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac
CAD ; diabetes ; electrocardiographic ; waves ; left bundle branch block ; nondiabetes ; dyslipidemia ; hypertension ; tobacco
receiver operating characteristic curve ; auc ; PCWP
trastuzumab-treated patients ; coronary artery disease ; hypertension ; trastuzumab administration ; CHF
LVEF ; clinical composite response ; cRT ON ; crte OFF ; LV ; end systolic volume index ; mL ; LV ; mass
tGF-β signaling ; tGF-β receptor ; smad ; c-Kit ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kit ; cell differentiation ; cardiomyocyte-like cells
hFrEF ; diuretics ; co-morbidities ; mwt ; mwt ; NYha
hf ; echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; mitral valve ; mva ; pressure gradient ; hg
systolic heart failure ; implantation ; ivabradine ; SHIFT ;Systolic Heart Failure Treatment ; If inhibitor ivabradine Trial ; ivabradine ; echocardiographic substudy
pse ; hg ; pse ; pse ; New York Heart association functional class
Renal function ; Chronic Kidney Disease Epidemiology ; glomerular filtration rate ; egFR
PARADIGm-HF ; chronic heart failure ; systolic dysfunction ;LV ; NYha ; bNP ; bNP ; primary endpoint ;cardiovascular death ; hospitalization ; heart failure ; ARNI ; lz696 ; sacubiltril ; valsartan
LV ; reverse remodeling ; pre-cRT ; ventricle ; left atrial ; ventricular ; end-diastolic ; ventricular ; ventricular
hyperkalemia ; African Americans ; no-AAs ; New York Heart association ;NYha ; class III ; HF ; left ventricular dysfunction ; spironolactone ; aldactone Evaluation Study ;RALes
iRS1 ; iRS2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS1 ; iRS2 ; heart-specific iRS1 ; iRS2 ; double-knockout ; h-dKO ; liver-specific iRS1 ; iRS2 double-knockout ; l-dKO
b-type natriuretic peptide ; n-terminal pro-B-type natriuretic peptide ; coronary artery disease ; bNP ; n-terminal fragment ; bNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers
ivabradine ; change ; diastolic mitral flow ; diastolic mitral annular velocity ; exercise capacity ; therapy ; ivabradine ; oxygen uptake
liberal transfusion protocols ; short-term mortality ; aggressive protocols ; acute coronary syndrome
death ; unplanned readmission
hEK ; embryonic kidney ; sphingosine-1-phosphate ; s1PR1 ; s1PR1 downregulation ; sphingosine-1-phosphate ; s1PR1 ; downregulation ; isoproterenol ; β-adrenergic receptor agonist
kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; depression ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; ventricular diastolic
cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration ; acute kidney injury
in conjunction ; diastolic function ; ventricular-arterial coupling
disease risk score ; dRS ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
i ; revascularization ; coronary artery bypass surgery ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram ; i
biomedical treatment ; biomedical treatment ; chm ; left ventricular ejection fraction ; left ventricular diastolic end diameter
heart failure ; left ventricular ejection fraction ; Arg16 ; grn27 ; gly16 ; figure ; β2-receptor ; carvedilol ; metoprolol
low-volume ED ; death ;hospitalization ; ed visit ; aOR ; high-volume ED ; aOR
Health Buddy Program ; risk-adjusted all-cause mortality ;hazard ratio ;HR ; inpatient admissions
multivariable-adjusted hazard ratios ; Mediterranean diet score ; DASh
ctnt ; NT-probNP ; aRIC HF ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; HF ; receiver operating characteristic curve ; auc ; discrimination improvement ; net reclassification improvement ; nRI
eplerenone ; hyperkalemia ; renal function ; wRF ; EMPHASIS-HF ; heart failure ; ejection fraction ;HF-ref ; New York Heart association ;NYha ; glomerular filtration rate ; egFR ; serum potassium
nesiritide ; cumulative urine volume ;nesiritide ; change ; cystatin c ;nesiritide
Nordic walking ; functional capacity ; mwt ; physical activity ; right grip strength ; depressive symptoms ;Hospital anxiety ; depression
hyperkalemia ; wRF ; diabetes ; egFR ; systolic blood pressure ; hg ; potassium ; hyperkalemia ; study-drug discontinuation ; hospitalization ; wRF ;hospitalization ; HF ; cardiovascular mortality
PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-AT ; dithiothreitol ; dt ; CDp ; choline ; 1-alkyl-2-acetyl-sn-glycerol ; cholinephosphotransferase ; pf-cp ; catabolic isoenzymes ; pf-acetylhydrolase ; pf-AH ; lipoprotein-associated phospholipase a2 ; lp-PLA
ivabradine group ; baseline ; follow-up exercise capacity ;mets ; oxygen uptake ; exercise-induced ; early diastolic mitral flow velocity ; early diastolic mitral ; annular
CHF ;Odds ration ; ht ; radiation ; hypertension ; genes coding ; NAD ; ph-oxidase subunit RAC2 ; hf ; doxorubicin efflux transporter
NYha classification ; class III ; change ; quality of life ; Duke Activity Status index ; hz ; Kansas City Cardiomyopathy Questionnaire ; walk
low-dose dopamine ; cumulative urine volume ;dopamine ; change ; cystatin c level ;dopamine
figure ; baseline glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; ventricular ejection fraction ; iCD shocks ; New York Heart association class ; atrial fibrillation ; congestive HF
oxygen uptake ; ventilatory efficiency slope ; hemoglobin ; ventricular ejection fraction ; renal function ; renal disease ; sodium
Kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; Fes ; natriuretic peptide ; mitral ; wave ratio
